Document:

EX-4.7

 Exhibit 4.7 

PATENT & TECHNOLOGY LICENSE AGREEMENT 

AGT. NO. A2014-1834 
 This
Patent & Technology License Agreement (“PTLA”) is by and between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”). 

Licensor owns, controls and/or has the right to license/sublicense the Licensed Subject Matter (defined in Exhibit A). Licensee desires to secure the right
and license to use, develop, manufacture, market, and commercialize the Licensed Subject Matter. Licensor desires to have the Licensed Subject Matter developed, exploited and used for the benefit of Licensee, the inventors, Licensor, and the public.

 NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the Parties hereby agree as follows: 

The Terms and Conditions of this PTLA are attached hereto as Exhibit A (the “Terms and Conditions”). In the event of a conflict between provisions
of this PTLA and the Terms and Conditions, the provisions in this PTLA shall govern. Unless defined in this PTLA, capitalized terms used in this PTLA shall have the meanings given to them in the Terms and Conditions. The section numbers used in the
left hand column in the table below correspond to the section numbers in the Terms and Conditions. 
  

											
	1.	  	 Definitions

		  	Effective Date	  	August 1 2014
			
		  	Licensor	  	Ohio State Innovation Foundation, with an address at 1524 North High Street, Columbus, OH 43201.
			
		  	Licensee	  	Cellectis, a French Société Anonyme, with its principal place of business at 8 rue de la Croix Jarry, 75013 Paris, France
			
		  	Territory	  	all countries and all regions Worldwide
			
		  	Field of Use	  	Field of Use: any and all activities (including without limitation research, development and commercialization) for Cancer Immunotherapy
		
	 	  	 Patent Rights

	 	  	 App. No./

Date of Filing
	  	 Title
	  	 Inventor(s)
	  	 Jointly Owned? (Y/N; if
Y, with whom?)
	  	 Prosecution Counsel

		  	PCT/US2014/036684 05/02/2014, T2013-213	  	CSI-Specific chimeric Antigen Receptor Engineered Immune Cells	  	Yu, Jianhua; Hofmeister, Craig; Chu, Jianhong	  	☐ Yes, 
w/[whom] 
☒ No	  	Meunier Carlin & Curfman
						
		  	61/819,141 05/03/2013, T2013-213	  	Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cells for Cancer Immunotherapy	  	Yu, Jianhua; Hofmeister, Craig; Chu, Jianhong	  	☐ Yes, 
w/[whom] 
☒ No	  	[Law firm]
						
		  	61/876,492 09/11/2013, T2013-213	  	Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cells for Cancer Immunotherapy (P2)	  	Yu, Jianhua; Hofmeister, Craig; Chu, Jianhong	  	☐ Yes, 
w/[whom] 
☒ No	  	[Law firm]

  

					
		  		  	
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	

							
	 Diligence Milestones, Fees and
Deadlines

	2.4, 3	  	Milestone Events	  	Milestone Fees Due by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events are achieved. For clarification, each milestone payment will be due only once upon the occurrence of the first
respective mentioned milestone event.	  	Deadlines
		  	1. First CAR screening to identify lead candidates concluded for Licensed Product covered by a Valid Claim	  	$0	  	August 1, 2015, subject to 20.3
				
		  	2. In vitro proof of concept completed for Licensed Product covered by a Valid Claim	  	$0	  	August 1, 2016, subject to 20.3
				
		  	3. In vivo proof of concept completed for Licensed Product covered by a Valid Claim	  	$0	  	August 1, 2017, subject to 20.3
				
		  	4. Filing of IND (or an equivalent Regulatory Authority application, if filed outside of the US) for Licensed Product covered by a Valid Claim	  	0	  	August 1, 2018, subject to 20.3
				
		  	5. Dosing of first patient in a Regulatory Authority-approved Phase 1 Clinical Trial of Licensed Product covered by a Valid Claim	  	$100,000 US	  	Within 12 months of receiving IND approval or approval from an equivalent Regulatory Authority
				
		  	6. Dosing of first patient in an Regulatory Authority-approved Phase II Clinical Trial of Licensed Product covered by a Valid Claim	  	$150,000 US	  	None
				
		  	7. Dosing of first patient in a Regulatory Authority-approved Phase III Clinical Trial of Licensed Product covered by a Valid Claim	  	$200,000 US	  	None
				
		  	8. Regulatory Approval of Licensed Product covered by a Valid Claim in a major licensed territory (US, EU or JP).	  	$1,000,000 US	  	None
				
		  	9. Regulatory Approval of Licensed Product covered by a Valid Claim in Russia, China, Brazil or India.	  	$500,000 US	  	None

							
	
	 Compensation

	3	  	Patent expenses due upon Effective Date	  	Current estimated amount. Licensee’s obligations to pay all past and future patent expenses pursuant to Section 6 (Patent Expenses and Prosecution) will not be limited by such amount.	  	Based on invoices received and approved as of: [Date]
August 31st 2014
	  	$390.00US
			
	3	  	Upfront Fee	  	$100,000US due on Effective Date
			
	3	  	License Maintenance Fees	  	 $0 US for Contract Year ending 2014

$20,000 US per Contract Year thereafter until first sale of Licensed Product covered by a Valid Claim

$0 US after first sale of Licensed Product

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	2	  	

							
	3	  	Sublicense 
Fees	  	None
				
	3.1	  	Running royalty rate (applies to Sales of Licensed Product covered by Valid Claims by Licensee, Affiliates and Sublicensees	  	On Net Sales of Licensed Products and/or Licensed Processes covered by a Valid Claim	  	1.5%; provided, however that the Running royalty rate applicable to Net Sales by a Sublicensee shall be the lesser of (a) 1.5% (or any reduced royalty pursuant to Section 20.2 of this PTLA ) of the Sublicensee’s Net Sales
or (b) fifteen percent (15% ) of the Royalty Sublicensing Consideration received by Licensee from such Sublicensees
			
	3.1	  	Minimum Annual Royalties	  	Starting on January 1st of the Contract Year following the first Sale of Licensed Product covered by a Valid Claim: US$100,000.00 (US$ One Hundred thousand) per
Contract Year.

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	3	  	

					
	18.	  	 Notices

		  	Licensee Contacts	  	Licensor Contacts
		  	 Contact for Notice:
 Attn:
CEO
 8 rue de la Croix Jarry, 75013 Paris—France

Fax: NA
 Phone: NA

E-mail: NA
  

Accounting contact:
 Attn: CEO

8, rue de la Croix Jarry, 75013 Paris -

France
 Fax: NA

Phone: NA
 E-mail: NA
  
 Patent prosecution contact:

Attn: Espinasse Sylvain

8, rue de la Croix Jarry, 75013 Paris -

France
 Fax: NA

Phone: NA
 E-mail: sylvain.espinasse@cellectis.com
  
 Business
development contact:
 Attn: Julia Berretta

8, rue de la Croix Jarry, 75013 Paris—France

Fax: +33 (0)1 81 69 16 06

Phone:+33 (0)1 81 69 16 51

E-mail: julia.berretta@cellectis.com
	  	 Contact for Notice:
 Attn:
President
 1524 N. High Street

Columbus, OH 43201
 Fax: 614-292-8907
 Phone: 614-292-1315
 E-mail:

techlicensing@osu.edu
  

Payment and reporting contact:
 Checks payable to “Ohio State
Innovation Foundation”
 Attn:

Accounting/Compliance

1524 N. High Street

Columbus, OH 43201
 Fax: 614-292-8907
 Phone: 614-292-1315
 E-mail:

OSIFcompliance@osu.edu
  

OSIF Patent Coordinator
 1524 N. High
Street
 Columbus, OH 43201

Fax: 614-292-8907

Phone: 614-292-1315

E-mail: tlcip@osu.edu
  

Patent prosecution contact:
 Attn: Brian
Giles
 [Address]
 Fax:
[Fax number]
 Phone:
1-678-869-7744
 E-mail:
 bgiles@mcciplaw.com

			
	
	 For Licensor Administrative Purposes
Only

	Changes to Standard Form Terms and Conditions	  	There have not been any revisions to Licensor’s standard form Terms and Conditions, except for revisions to the following sections: 1, 2.1, 2.2, 2.3, 2.4, 3.1, 4, 5.4, 5.5, 6.1, 7.1, 7.3, 8, 9.2, 10, 11.1, 11.2, 12,13, 14, 15,
17, 19.4, and 19.8.

 20. Special Provision. The Parties hereby agree to the following special provisions (if
any) set forth in this Section 20 with respect to this PTLA. 
 20.1 Milestone Definitions 

“Phase I Clinical Trial” means any clinical study conducted to initially evaluate the safety, metabolism, pharmacologic
actions, side effects associated with and if possible early evidence of effectiveness of Licensed Product in humans. 
 “Phase II
Clinical Trial” means any clinical study conducted to evaluate the effectiveness of Licensed Product for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term
side effects and risks associated with License Product 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	4	  	

 “Phase III Clinical Trial” means any clinical study conducted to gather the
additional information about the effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of Licensed Product. 

“Regulatory Approval” means the approval needed by the Regulatory Authority for a particular national jurisdiction to market,
Sell and use a Licensed Product or Licensed Service in that national jurisdiction. 
 “Regulatory Authority” means the
governmental authority responsible for granting any necessary licenses or approvals for the marketing, Sale and use of a Licensed Product or Licensed Service in a particular national jurisdiction, including without limitation FDA, European Medicines
Agency or Koseisho (i.e., the Japanese Ministry of Health and Welfare). 
 20.2 Stacking of Royalty Payments. In the event that a
Licensed Product / Licensed Process cannot be used, developed, manufactured, marketed, and/or commercialized without infringing the issued patent or patents owned or controlled by a third party (“Third Party Patents”), and if Licensee (or
its Affiliates and Sublicensees) pays a royalty to such third party for rights to use such Third Party Patents in connection with the Sale of Licensed Products / Licensed Processes (the “Third Party Royalty Payment”), then 50% of such
Third Party Royalty Payment may be credited against the running royalties payable on the Net Sales for those Licensed Products which practice the Third Party Patents, but in no event shall such credits reduce the royalty rate payable to Licensor
below 0.5% of such Net Sales. 
 By way of example, if Licensee makes a Third Party Royalty Payment under this Section of 1%, then a credit
of 0.5% will be applied towards running royalties payable hereunder, reducing the royalties payable on Net Sales with respect to such Sale from 1.5% to 1.0%. If Licensee wishes to invoke this provision, written notification must be provided to
Licensor indicating the identity of the Third Party, the rate of the Third Party Royalty Payment, and a description of the Third Party Patents that will be / are incorporated into the Licensed Product / Licensed Process. If such Third Party Patents
license agreement with Licensee includes a royalty stacking provision of like intent to the present Section, the royalty rate reduction provided for in this section will be calculated as if such provision in such other license were absent. Any such
deductions from Licensee shall be detailed to Licensor, upon Licensor’s request. 
 20.3 Milestone Extension Option. Licensee
shall have the option to extend the deadlines for all those Milestone Events specified in said Section 2.4,3 in six (6) months increments with a maximum extension of two (2) years by paying the following milestone extension Fees: 

lst six (6) month extension fee - $0 US 

2nd six (6) month extension fee- $12,500 US

 3rd six (6) month extension fee- $25,000
US 
 4th six (6) month extension fee-
$50,000 US 
 This option may only be exercised at a time when Licensee is in compliance with all of its obligations under the Agreement,
including having met all milestones with deadlines prior to the date such notice is given (without giving effect to the extension resulting from the exercise of such option). In order to exercise this option, Licensee must provide Licensor written
notice of its exercise of this option accompanied by payment of the milestone extension fee. Such notice must contain an affirmation from the Licensee that it is in compliance with all of its obligations under the Agreement, that it is currently
Diligently Commercializing Licensed Products or Licensed Services and that it reasonably expects to meet the milestone deadlines as extended by the exercise of such option. Upon such payment and exercise, each of the future milestones deadline dates
shall be extended by the duration of the extension. 
 21. No Other Promises and Agreements: Representation by Counsel. Each Party
expressly represents and warrants and does hereby state and represent that no promise or agreement which is not herein expressed has been made to it in executing this PTLA except those explicitly set forth herein and in the Terms and Conditions, and
that such Party is not relying upon any statement or representation of the other Party or its representatives except those explicitly set forth herein and in the Terms and Conditions. Each Party is relying on its own judgment and has had the
opportunity to be represented by a legal counsel. Each Party hereby represents and warrants that it understands and agrees to all terms and conditions set forth in this PTLA and said Terms and Conditions. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	5	  	

 22. Deadline for Execution by Licensee. If this PTLA is executed first by a Party
(the “Initiating party”) and is not executed by the other Party and received by the Initiating Party at the address and in the manner set forth in Section 18 of the Terms and Conditions within sixty (60) days of the date of
signature set forth under the Initiating Party’s signature below, then this PTLA shall be null and void and of no further effect. 
 IN
WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this PTLA. 
  

									
	LICENSOR: OHIO STATE INNOVATION FOUNDATION	 	LICENSEE: Cellectis SA
					
	BY:	 	 /s/ Erin Bender
	 		 	BY:	 	 /s/ André CHOULIKA

		 	Name: Erin Bender	 		 	NAME: André CHOULIKA
		 	Title: Vice President	 		 	TITLE: Chief Executive Officer
			
	DATE: 23 October 2014	 		 	DATE: October 15, 2014

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	6	  	

 EXHIBIT A 

TERMS AND CONDITIONS OF THE PTLA 
 These
Terms and Conditions of the PTLA (“Terms and Conditions”) are incorporated by reference into the PTLA to which they are attached. All Section references in these Terms and Conditions shall be references to provisions in these Terms and
Conditions unless explicitly stated otherwise. 
  

	1.	 Definitions. 

“Affiliate” means any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any
business entity that is more than 50% owned by a business entity that owns more than 50% of Licensee. 
 “Agreement” means collectively
(i) these Terms and Conditions, and (ii) the PTLA. 
 “Confidential Information” means all information that is of a confidential
and proprietary nature to Licensor or Licensee and provided by one Party (“Discloser”) or made available to the other Party (“Recipient”) under the Agreement, and this Agreement. 

“Contract Quarter” means the three-month periods ending on March 31, June 30, September 30, and December 31. “Contract
Year” means the 12-month periods ending on December 31. 
 “Effective Date”, “Field of
Use”, “Inventors” (or singly, “Inventor”), “Licensee”, “Licensor”, “Prosecution Counsel”, and “Territory” mean, respectively, the date
indicated as the Effective Date, the field indicated as the Field of Use, the inventors identified in the definition of Patent Rights, the Party identified as the Licensee, the Party identified as the Licensor, the law firm or attorney who is
handling the prosecution of the Patent Rights, and the territory, all as identified in Section 1 of the PTLA. 
 “Government” means
any agency, department or other unit of the United States of America or the State of Ohio. 
 “Gross Consideration” means all cash and non-cash consideration (e.g., securities). 
 “Licensed Process” means a method, procedure, process,
performance of a service, or other subject matter: (i) whose practice, use, sale, or offer for sale is covered in whole or in part by a Valid Claim of the Patent Rights; and/or (ii) that uses, incorporates, is made with, is created from,
is derived or developed from the use of any Licensed Products or modifications of, enhancements to, and/or derivatives of the Licensed Products. 

“Licensed Product” means any product, apparatus, kit, portion, part, or component thereof: (i) whose manufacture, use, sale, offer for
sale or import is covered in whole or in part by a Valid Claim of the Patent Rights; (ii) that is made by using a Licensed Process or another Licensed Product; and/or (iii) that is derived or developed from a Licensed Process or another
Licensed Product. 
 “Licensed Subject Matter” means Patent Rights. 

“Milestone Fees” means all Fees identified as Milestone fees in Sections 2.4, 3 of the PTLA. 

“Net Sales” means the Gross Consideration received by Licensee, its Affiliates and Sublicensees from the Sale of Licensed Products and
Licensed Processes, less the following items directly attributable to the Sale of such Licensed Products and Licensed Processes that are specifically identified on the invoice for such Sale and borne by the Licensee, its Affiliates or Sublicensees
as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding income taxes; (c) import and export duties actually paid; (d) freight,
transport, packing and transit insurance charges actually paid or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the original invoiced amount. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	7	  	

 “PTLA” means the particular Patent & Technology License Agreement to which these
Terms and Conditions are attached and incorporated. 
 “Patent Rights” means: (a) the patents and patent applications listed in
Section 1 of the PTLA; (b) all non-provisional patent applications that claim priority to any of the provisional applications listed in Section 1 of the PTLA to the extent the claims of such non-provisional applications are entitled to claim priority to such provisional applications; (c) all divisional(s), continuation(s) and
continuations-in-part (excluding new matter and claims containing new matter) of the non-provisional patent applications
identified in (a) and (b) above, to the extent that claims of such continuations-in-part are entitled to claim priority to at least one of the patent applications
identified in (a) or (b) above; (d) all reissues, reexaminations, extensions, and foreign counterparts of any of the patents or patent applications identified in (a), (b) or (c), above; and (e) any patents that issue with respect to
any of the patent applications listed in (a), (b), (c) or (d), above. 
 “Quarterly Payment Deadline” means the day that is forty-five
(45) days after the last day of any particular Contract Quarter. 
 “Royalty Sublicensing Consideration” means the earned royalties
received by the Licensee or its Affiliate, directly or indirectly, from any Sublicensee in consideration for the Net Sales. 
 “Sell, Sale or
Sold” means any transfer or other disposition of Licensed Products or Licensed Processes for which consideration is received by Licensee, its Affiliates or Sublicensees. A Sale of Licensed Products or Licensed Processes will be deemed
completed at the time Licensee or its Affiliate or its Sublicensee receives such consideration. 
 “Sublicense Agreement” means any
agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any third party any of the license or sublicense rights granted to the Licensee under the Agreement. 

“Sublicense Fee” means the fee specified in Section 3 of the PTLA. 

“Sublicensee” means any entity that enters into an agreement or arrangement with Licensee or receives a sublicense grant from Licensee under
the Licensed Subject Matter, to manufacture, have manufactured, offer for Sale, Sell, lease, use, practice, and/or import the Licensed Product and/or Licensed Process. 

“Valid Claim” means any issued claim of the Patent Rights that has not expired, or been finally held as invalid or unenforceable by a court
or administrative body of competent jurisdiction from which no appeal can be or is taken, as well as any pending claim of the Patent Rights that has not been finally and conclusively rejected from which no appeal can be or is taken. 

 

	2.	 License Grant and Commercialization. 

 

	 	2.1	 Grant. 

 

	 	(a)	 Licensor grants to Licensee a royalty-bearing exclusive license under Patent Rights, to make, have made,
distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products and Licensed Processes in the Field of Use in the Territory. 

 

	 	(b)	 [Intentionally left blank] 

 

	 	(c)	 This grant is subject to: (l)the payment by Licensee to Licensor of all consideration required under the
Agreement; (2) any rights of, or obligations to, the Government (subject to clause 11.2 herein); and (3) rights retained by Licensor to (i) publish the scientific findings from research related to the Licensed Subject Matter,
(ii) use the Licensed Subject Matter for teaching, research, education, and other educationally-related purposes, and (iii) grant rights to, and transfer material embodiments of, the Licensed Subject Matter to other academic institutions
or non-profit research institutions for the purposes identified in clauses (i) and (ii) above. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	8	  	

	 	(d)	 Licensor reserves all rights not expressly granted in the Agreement including, but not limited to, any other
licenses, implied or otherwise, to any patents or other rights of Licensor, regardless of whether such patents or other rights are dominant or subordinate to any rights expressly granted in the Agreement, or are required to exploit any rights
expressly granted in the Agreement. 

  

	 	2.2	 Affiliates. The license granted herein extends to any Licensee’s Affiliate listed in
Appendix 2 herein and Licensee will be responsible for its Affiliates compliance with the terms herein. For the sake of clarity, any specific reference to “Licensee” herein shall include such Affiliate regardless of whether a specific
reference to an “Affiliate” is made in such provision. Licensee may update the list of its Affiliates as set forth in Appendix 2, during the term of this Agreement, upon written notification to Licensor. 

 

	 	2.3	 Sublicensing. Licensee has the right to grant Sublicense Agreements under the Licensed Subject
Matter consistent with the terms of the Agreement, subject to the following: 

  

	 	(a)	 A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee must
agree in writing to be bound by the applicable terms and conditions of this Agreement and shall indicate that Licensor is a third party beneficiary of the Sublicense Agreement. 

 

	 	(b)	 Licensee shall deliver to Licensor a summary of each Sublicense Agreement granted by Licensee, Affiliate or
Sublicensee, and any modification or termination thereof, within sixty (60) days following the applicable execution, modification, or termination of such Sublicense Agreement. Any such summary shall include relevant information, as reasonably
determined by Licensor, for Licensor to evaluate the potential financial consideration the Licensor would obtain from Licensee having entered into such sublicense Agreement as well as any relevant information related to section 2.4 below.

  

	 	(c)	 Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all of the
Licensee’s duties and obligations contained in the Agreement. Each Sublicense Agreement will contain a right of termination by Licensee in the event that the Sublicensee breaches the payment or reporting obligations affecting Licensor or any
other terms and conditions of the Sublicense Agreement that would constitute a breach of the Agreement if such acts were performed by Licensee. 

  

	 	2.4	 Diligent Commercialization. Licensee by itself or through its Affiliates and Sublicensees will
use diligent and commercially reasonable efforts to commercialize Licensed Products and/or Licensed Processes in the Field of Use within the Territory. Without limiting the foregoing, Licensee will: (a) maintain a bona fide, funded, ongoing and
active research, development, manufacturing, marketing, and/or sales program to diligently make, have made, use, sell, and have sold Licensed Products and/or Licensed Processes that are commercially available to the public as soon as commercially
practicable, and (b) fulfill the milestone events specified in Section 2.4,3 of the PTLA by the deadlines indicated therein. If the obligations under this Section 2.4,3 are not fulfilled, Licensor may treat such failure as a breach in
accordance with Section 7.3(b). 

  

	3.	 Compensation. In consideration of rights granted to Licensee, Licensee will pay Licensor
all of the fees and royalties set forth in the PTLA and these Terms and Conditions. Each payment will reference the PTLA number and will be sent to Licensor’s payment and accounting contact in Section 18 of the PTLA. 

 

	 	3.1	 Royalties. Licensee will pay running royalties on Net Sales in each Contract Quarter on or before
the Quarterly Payment Deadline for such Contract Quarter at the rate set forth in Section 3.1 of the PTLA. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	9	  	

	 	
If royalties paid to Licensor do not reach the minimum royalty amounts stated in Section 3.1 of the PTLA in the stated period, then forty-five (45) days after the end of such period,
Licensee will pay Licensor an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid to Licensor. 

  

	4.	 Reports and Plans. Utilizing the report forms in Appendix 1, Licensee will provide to
Licensor’s payment and reporting contact the following reports, including but not limited to: (a) milestone, commercialization plan update report and annual written progress report on January 31; and (b) quarterly payment and royalty
report. 

  

	5.	 Payment. Records, and Audits. 

 

	 	5.1	 Payments. AN amounts referred to in the PTLA are expressed in U.S. dollars without deductions for
taxes, assessments, fees, or charges of any kind. Each payment will reference the Agreement number set forth at the beginning of the PTLA. AH payments to Licensor will be made in U.S. dollars by check or wire transfer (Licensee to pay all wire
transfer fees) payable to the payee identified in Section 18 and sent to the payment and reporting contact in Section 18. Licensee may not make any tax withholdings from payments to Licensor. 

 

	 	5.2	 Sales Outside the U.S. If any currency conversion shall be required in connection with the
calculation of payments hereunder, such conversion shall be made using the rate used by Licensee for its financial reporting purposes in accordance with Generally Accepted Accounting Principles (or foreign equivalent). 

 

	 	5.3	 Late Payments. Amounts that are not paid when due will accrue a late charge from the due date
until paid, at a rate equal to 1.0% per month (or the maximum allowed by law, if less). 

  

	 	5.4	 Records. For a period of six (6) years after the Contract Quarter to which the records
pertain, Licensee agrees that it and its Affiliates and Sublicensees will each keep complete and accurate records of their Sales, Net Sales, royalty payment calculations, and Milestone Fees in sufficient detail to enable such payments to be
determined and audited in accordance with Section 5.5 hereafter. 

  

	 	5.5	 Auditing. Licensee and its Affiliates will permit Licensor or its representatives, at
Licensor’s expense, to periodically examine books, ledgers, and records during regular business hours, at Licensee’s or its Affiliate’s place of business, on at least thirty (30) days advance notice, to the extent necessary to
verify any payment or report required under the Agreement. For each Sublicensee, Licensee shall obtain such audit rights for itself and use reasonable efforts to obtain audit rights for Licensor. It is agreed that in the event Licensee does not
reasonably obtain Licensor’s right to audit a Sublicensee’s books, ledgers, and records, Licensee may audit such Sublicensee upon Licensor’s reasonable request (and expense). If Licensee conducts an audit of the Sublicensee’s
records, Licensee will furnish to Licensor a copy of the findings from such audit to the extent affecting any Licensor’s payment or report required under the Agreement. No more than one audit of Licensee, each Affiliate, and each Sublicensee
shall be conducted under this Section 5.5 in any calendar year. If any amounts due to Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount of such underpayment plus accrued interest due in accordance with
Section 5.3. If the amount of underpayment is equal to or greater than 5% of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits may, at Licensor’s sole discretion, consist of a
self-audit conducted by Licensee at Licensee’s expense and certified in writing by an authorized officer of Licensee. All information examined pursuant to this Section 5.5 shall be deemed to be the Confidential Information of the Licensee.

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	10	  	

	6.	 Patent Expenses and Prosecution. 

 

	 	6.1	 Patent Expenses. Licensee shall pay Licensor for all past patent expenses as set forth in
Section 3 of the PTLA. Licensee shall pay any past patent expenses as well as all future patent expenses incurred by Licensor regarding the Patent Rights within forty-five (45) days after Licensee’s receipt of an invoice from
Licensor. Patent expense payment delinquencies (whether owed directly to Prosecuting Counsel or to Licensor) will be considered a payment default under Section 7.3(a). 

 

	 	6.2	 Direction of Prosecution. Licensor shall control the preparation, prosecution and maintenance of
the Patent Rights. Licensor will consider input from Licensee regarding thoughts and strategies for the preparation, prosecution and maintenance of the Patent Rights. Licensor will request that copies of all material documents received by
Prosecution Counsel from patent offices regarding the Patent Rights and the material documents prepared by Prosecution Counsel for submission to patent offices be provided to Licensee for review and comment prior to filing to the extent practicable
under the circumstances. 

  

	 	6.3	 Ownership. All patent applications and patents will be in the name of Licensor (and any co-owner identified in Section 1 of the PTLA) and owned by Licensor (and such co-owner, if any). 

 

	 	6.4	 Foreign Filings. In addition to the U.S., the Patent Rights shall, subject to applicable bar
dates, be pursued in such foreign countries as Licensee so designates in writing to Licensor in sufficient time to reasonably enable the preparation of such additional filings, and in those foreign countries in which Licensor has filed applications
prior to the Effective Date. If Licensee does not choose to pursue patent rights in a particular foreign country and Licensor chooses to do so, Licensee shall so notify Licensor and thereafter said patent application or patent shall no longer be
included in the Patent Rights and Licensee shall have no further rights thereto. Licensor shall have the right to make alternative arrangements with Licensee for upfront payment of foreign patent expenses. 

 

	 	6.5	 Withdrawal from Paying Patent Costs. If at any time Licensee wishes to cease paying for any costs
for a particular Patent Right or for patent prosecution in a particular jurisdiction, Licensee must give Licensor at least ninety (90) days prior written notice and Licensee will continue to be obligated to pay for the patent costs which
reasonably accrue during said notice period. Thereafter, said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. 

 

	7.	 Term and Termination. 

 

	 	7.1	 Term. Unless earlier terminated as provided herein, the term of the Agreement will commence on
the Effective Date and continue until the last to expire Valid Claim or termination of the Patent Rights. 

  

	 	7.2	 Termination by Licensee. Licensee, at its option, may terminate the Agreement by providing
Licensor written notice of termination and such termination will become effective ninety (90) days after receipt of such notice by Licensor. 

  

	 	7.3	 Termination by Licensor. Licensor, at its option, may immediately terminate the Agreement, or any
part of Licensed Subject Matter, or any part of Field of Use, or any part of Territory, or the exclusive nature of the license grant, upon delivery of written notice to Licensee of Licensor’s decision to terminate, if any of the following
occur: 

  

	 	(a)	 Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make the required
payment within sixty (60) days after delivery of written notice from Licensor; or 

  

	 	(b)	 Licensee is in breach of any non-payment provision of the Agreement,
and does not cure such breach within sixty (60) days after delivery of written notice from Licensor; or 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	11	  	

	 	(c)	 Licensee or its Affiliate initiates any proceeding or action to challenge the validity, enforceability, or
scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action. Upon Licensor’s request, Licensee shall terminate any Sublicense Agreement with a Sublicensee that initiates any proceeding or action to
challenge the validity, enforceability, or scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action. 

  

	 	7.4	 Other Conditions of Termination. The Agreement will terminate: 

 

	 	(a)	 Immediately without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee files
a bankruptcy action or becomes bankrupt or insolvent, or (ii) Licensee’s Board of Directors elects to liquidate its assets or dissolve its business, or (iii) Licensee ceases its business operations, or (iv) Licensee makes an
assignment for the benefit of creditors, or (v) if the business or assets of Licensee are otherwise placed in the hands of a receiver, assignee or trustee, whether by voluntary act of Licensee or otherwise; or 

 

	 	(b)	 At any time by mutual written agreement between Licensee and Licensor. 

 

	 	7.5	 Effect of Termination. If the Agreement is terminated for any reason: 

 

	 	(a)	 All Sublicenses that are granted by Licensee pursuant to this Agreement where the Sublicensee is in compliance
with its Sublicense Agreement as of the date of such termination will remain in effect and will be assigned to Licensor, except that Licensor will not be bound to perform any duties or obligations set forth in any Sublicenses that extend beyond the
duties and obligations of Licensor set forth in this Agreement; and 

  

	 	(b)	 Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to sell,
leasing, loaning and importing any Licensed Products and performing Licensed Processes by the effective date of termination; and 

  

	 	(c)	 Licensee immediately shall tender payment of all accrued royalties and other payments due to Licensor as of the
effective date of termination; and 

  

	 	(d)	 Nothing in the Agreement will be construed to release either Party from any obligation that matured prior to
the effective date of termination; and 

  

	 	(e)	 The provisions of Sections 8 (Confidentiality), 9.4 (Cooperation), 11 (Representations and Disclaimers), 12
(Limit of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General Provisions) will survive any termination or expiration of the Agreement. In addition, the provisions of Sections 3 (Compensation), 4 (Reports
and Plans), 5 (Payment, Records and Audits), and 6.1 (Patent Expenses) shall survive with respect to all activities and payment obligations accruing prior to the termination or expiration of the Agreement. 

 

	8.	 Confidentiality. Recipient will use reasonable care to safeguard the confidentiality of
the Confidential Information and will not provide any Confidential Information to third parties without Discloser’s prior written consent or use the Confidential Information of the Discloser for any purpose other than as strictly permitted
under this Agreement. Recipient will permit its employees to have access to the Confidential Information only on a need-to-know basis, and then only on the basis of a
clear understanding by these individuals of the obligations hereunder. Recipient is under no obligation for any Confidential Information which: (a) it can demonstrate by written records was previously and legally known to it; (b) is now,
or becomes in the future, public knowledge other than through its own acts or omissions; (c) it independently develops by those not having access to the Confidential Information and which can be proven through verifiable records; (d) it
lawfully obtains from a source independent of the Discloser not bound by 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	12	  	

	 	
confidentiality and restricted use obligations with regard to such Confidential Information; or (e) is required by applicable law to be disclosed provided that if Recipient is required to
make any such disclosure of the Discloser’s Confidential Information, to the extent it may legally do so, it will give reasonable advance written notice to Discloser of such disclosure and will reasonably cooperate with the Discloser to secure
confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise). Neither Party shall make any public announcement regarding this Agreement without the express written consent of the other Party.
Licensee and its Affiliates shall only be entitled to disclose, on a need to know basis, Confidential Information, and the existence of this Agreement to an acquirer of all or substantially ail of the assets of the business to which this Agreement
pertains or potential Sublicensees provided that Licensee (or its relevant Affiliate) has previously bound such potential acquirer or Sublicensee by confidentiality and restricted use obligations at least as stringent than those set forth in this
Agreement. Subject to the exclusions listed above, the Parties’ confidentiality obligations under the Agreement will survive termination of the Agreement and will continue for a period of five (5) years thereafter. 

 

	9.	 Infringement and Litigation. 

 

	 	9.1	 Notification. If either Licensor’s designated office for technology commercialization or
Licensee becomes aware of any infringement or potential infringement of Patent Rights, each Party shall promptly notify the other of such in writing. 

  

	 	9.2	 Licensee’s Enforcement Rights. Licensee shall have the first right but not the obligation to
enforce the Patent Rights against any infringement by a third party in the Field in the Territory, within a period of six (6) months from notice of such infringement. Licensee shall be responsible for payment of ail fees and expenses associated
with such enforcement incurred by Licensee and reasonably incurred by Licensor in providing cooperation or joining as a party as provided in Section 9.4. Ten percent (10%) any monetary recovery for actual damages or punitive damages, in excess
of Licensee’s documented, third-party expenses in enforcing the Patent Rights and amounts actually reimbursed by Licensee to Licensor under this Section 9.2, shall be shared with Licensor. 

 

	 	9.3	 Licensor’s Enforcement Rights. If Licensee does not file suit within six (6) months
after a written request by Licensor to initiate an infringement action or earlier if Licensee provides written notice to Licensor that Licensee will not initiate infringement action, then Licensor shall have the right, at its sole discretion, to
bring suit to enforce any Patent Right licensed hereunder against the infringing activities, with Licensor retaining all recoveries from such enforcement. 

  

	 	9.4	 Cooperation between Licensor and Licensee. In any infringement suit or dispute, the Parties agree
to cooperate fully with each other in a reasonable manner. If it is necessary to name Licensor as a party in such action, then Licensee must first obtain Licensor’s prior written permission, which permission shall not be unreasonably withheld,
provided that Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor. 

  

	10.	 Export Compliance. Licensee shall observe all applicable United States and foreign laws
and regulations with respect to the research, development, manufacture, marketing and transfer of Licensed Products and related technical data, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export
Administration Regulation. Licensee hereby represents and covenants that Licensee: (a) is neither a national of, nor controlled by a national of, any country to which the United States prohibits the export or
re-export of goods, services, or technology; (b) is not a person specifically designated as ineligible to export from the United States or deal in U.S.-origin goods, services, or technologies;
(c) shall not export or re-export, directly or indirectly, any Licensed Products and Licensed Processes to any country or person (including juridical persons) to which the United States prohibits the
export of goods, technology or services; and (d) in the event that a United States government license or authorization is required for an export or re-export of goods, services, or technology (including
technical information acquired from Licensor under this Agreement and/or any products created by using such technical information or any part 

  

					
		  	13	  	
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	

	 	
thereof), shall obtain any necessary United States government license or other authorization prior to undertaking the export or re- export. Licensee shall
include a provision in its agreements, substantially similar to this Section 10, with its Sublicensees, third party persons or entities who purchase a Licensed Product, requiring that these parties comply with all then-current applicable export
laws and regulations and other applicable laws and regulations. 

  

	11.	 Representations and Disclaimers. 

 

	 	11.1	 Licensor Representations. Subject to Clause 11.2 herein, Licensor represents and warrants to
Licensee that to its best knowledge, having conducted a diligence review of the Licensed Subject Matter: (a) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights (other than the right, title and
interest of any joint owner identified in Section 1 of the PTLA), (b) Licensor has the right to grant the license and sublicense hereunder, and (c) Licensor has not knowingly granted and will not knowingly grant licenses or other rights
under the Patent Rights that are in conflict with the terms and conditions in the Agreement. 

  

	 	11.2	 Government Rights. Licensor represents and warrants that the Licensed Subject Matter have not
been developed under a funding agreement with Government. The Agreement is made subject to the Government’s rights under any such agreement and under any applicable Government law or regulation and Licensor shall immediately inform Licensee if
it becomes aware of any Government’s right under the Licensed Subject Matter and this Agreement. To the extent that there is a conflict between any such agreement, such applicable law or regulation and the Agreement, the terms of such
Government agreement, and applicable law or regulation, shall prevail. 

  

	 	11.3	 Licensor Disclaimers. EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE UNDERSTANDS AND
AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED PROCESSES OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE,
MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, NONINFRINGEMENT, AND/OR BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY CLAIM OR PATENT WITHIN
PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN THE FIELD OF USE. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY
IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS SPECIFICALLY DESCRIBED HEREIN.

  

	 	11.4	 Licensee Representation. By execution of the Agreement, Licensee represents, acknowledges,
covenants and agrees (a) that Licensee has not been induced in any way by Licensor or its employees to enter into the Agreement; (b) that Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items
and issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the Agreement; (c) that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to
adequately conduct the due diligence; and (d) that Licensee accepts all risks inherent herein.Licensee represents that it is a duly organized, validly existing entity of the form indicated in Section 1 of the PTLA, and is in good standing
under the laws of its jurisdiction of organization as indicated in Section 1 of the PTLA, and has all necessary corporate or other appropriate power and authority to execute, deliver and perform its obligations hereunder. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	14	  	

	12.	 Limit of Liability. IN NO EVENT SHALL LICENSEE, LICENSOR, OSU, OR THEIR INVENTORS,
OFFICERS, EMPLOYEES, STUDENTS, TRUSTEES, AGENTS, OR AFFILIATED ENTERPRISES, BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE)
ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. 

 

	13.	 Indemnification Obligation. Licensee agrees to hold harmless, defend and indemnify
Licensor, its Affiliates, and their officers, employees, students, inventors, trustees, agents, and consultants (“Indemnified Parties”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines,
losses, costs and expenses (including, without limitation, reasonable attorneys’ fees and other expenses of litigation) (collectively “Liabilities”) resulting from claims or demands brought by third parties against an Indemnified
Party on account of any injury or death of persons, damage to property, or any other damage or loss arising out of or in connection with the Licensee’s performance of this Agreement or the exercise or practice by or under authority of Licensee,
its Affiliates or their Sublicensees, or third party person or entity who purchases a Licensed Product, of the rights granted hereunder. Licensee shall have no responsibility or obligation under this section for any Liabilities to the extent caused
by the gross negligence or willful misconduct by Licensor. 

  

	14.	 Insurance Requirements. Prior to any Licensed Product or Licensed Process being used or
Sold (including for the purpose of obtaining regulatory approval), by Licensee or an Affiliate, and for a period of five years after the Agreement expires or is terminated, Licensee shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in commercially reasonable and appropriate amounts for the Licensed Product or Licensed Process being used or Sold. Licensee shall impose such insurance obligations to its Sublicensees. Such commercial general
liability insurance shall provide, without limitation: (a) product liability coverage; and (b) broad form contractual liability coverage for Licensee’s indemnification under the Agreement. Upon request by Licensor, Licensee shall
provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide Licensor with written notice of at least sixty (60) days prior to Licensee cancelling, not renewing, or materially changing such insurance.

  

	15.	 Assignment. This Agreement is not assignable by Licensee without the prior written consent
of Licensor, which consent will not be unreasonably withheld. For any permitted assignment to be effective, (a) Licensee must be in good standing under this Agreement, and (b) the assignee must assume in writing (a copy of which shall be
promptly provided to Licensor) all of Licensee’s interests, rights, duties and obligations under the Agreement and agree to comply with all terms and conditions of the Agreement as if assignee were an original Party to the Agreement.

  

	16.	 Patent Markings. Licensee agrees that all Licensed Products Sold by Licensee, Affiliates,
and Sublicensees will be marked in accordance with each country’s patent marking laws, including Title 35, U.S. Code, in the United States. 

  

	17.	 Use of Name. Either Party will not use the name, trademarks or other marks of the other
Party without the advance written consent of the other Party, which consent may be revoked at any time by the other Party. 

  

	18.	 Notices. Any notice or other communication of the Parties required or permitted to be
given or made under the Agreement will be in writing and will be deemed effective when sent in a manner that provides confirmation or acknowledgement of delivery and received at the address set forth in Section 18 of the PTLA (or as changed by
written notice pursuant to this Section 18). Notices required under the Agreement may be delivered via E-mail provided such notice is confirmed in writing as indicated. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	15	  	

	19.	 General Provisions. 

 

	 	19.1	 Binding Effect. The Agreement is binding upon and inures to the benefit of the Parties herein,
their respective executors, administrators, heirs, permitted assigns, and permitted successors in interest. 

  

	 	19.2	 Construction of Agreement. Both Parties agree that any ambiguity in the Agreement shall not be
construed more favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement. 

  

	 	19.3	 Counterparts and Signatures. The Agreement may be executed in multiple counterparts, each of
which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. A Party may evidence its execution and delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or
email. 

  

	 	19.4	 Compliance with Laws. Licensee and Licensor will comply with all applicable federal, state and
local laws and regulations. 

  

	 	19.5	 Governing Law; Jurisdiction. The Agreement will be construed and enforced in accordance with laws
of the State of Ohio, without regard to choice of law and conflicts of law principles. The Parties agree that any claim or cause of action regarding this Agreement shall be brought in a court of competent jurisdiction in Ohio and this is the
parties’ sole and exclusive process for seeking a remedy for any and all claims and causes of action regarding this Agreement. 

  

	 	19.6	 Modification. Any modification of the Agreement will be effective only if it is in writing and
signed by duly authorized representatives of both Parties. 

  

	 	19.7	 Severability. If any provision hereof is held to be invalid, illegal or unenforceable in any
jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full force and effect in
such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other
provisions in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable. 

  

	 	19.8	 Third Party Beneficiaries. Nothing in the Agreement, express or implied, is intended to confer
any benefits, rights or remedies on any entity, other than the Parties, their affiliates, and their permitted successors and assigns. However, if there is a joint owner of any Patent Rights identified in Section 1 of the PTLA (other than
Licensee), then Licensee hereby agrees that the following provisions of these Terms and Conditions extend to the benefit of the co-owner identified therein (excluding the Licensee to the extent it is a co-owner) as if such co-owner was identified in each reference to the Licensor: the retained rights under Section 2.1(d); Section 11.3 (Licensor Disclaimers);
Section 12 (Limitation of Liability); Section 13 (Indemnification); Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable). 

 

	 	19.9	 Waiver. Neither Party will be deemed to have waived any of its rights under the Agreement unless
the waiver is in writing and signed by such Party. No delay or omission of a Party in exercising or enforcing a right or remedy under the Agreement shall operate as a waiver thereof. 

 

	 	19.10	 Sovereign Immunity. Nothing in the Agreement shall be deemed or treated as any waiver of
OSU’s sovereign immunity. 

  

	 	19.11	 Cross Default. In the event that Licensee is a party to any other agreement with Licensor, a
default by Licensee of this or any other agreement shall be deemed a default under all other agreements with Licensor and OSU. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	16	  	

	 	19.12	 Entire Agreement. The Agreement constitutes the entire agreement between the parties regarding
the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings relative to such matters. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	17	  	

 Appendix 1A 

OSIF DILIGENCE: MILESTONES, FEES, & DEADLINES 
  

			
	
Licensee:                        
                                         
               

Inventor:                        
                                         
               
 Period Covered
From:                                        
                   
 Prepared
By:                                        
                                  

Approved
By:                                        
                                
	 	 Agreement
No:                                        
                                        

OSIF’s Tech ID
No:                                        
                                

Through:                        
                                         
                         

Date:                         
                                         
                              

Date:                         
                                         
                              

  

							
	 Milestone Events
	  	 Milestone Fees

Due by the Quarterly Payment
Deadline for the Contract Quarter
in which the milestone events are
achieved
	  	 Deadlines
	  	 Date Completed and Short
Description of Activity (use
space
below)

	 1.
	  	$	  		  	
	  
	  	  
	  	  
	  	  

	 2.
	  	$	  		  	
	  
	  	  
	  	  
	  	  

	 3.
	  	$	  		  	
	  
	  	  
	  	  
	  	  

	 4.
	  	$	  		  	
	  
	  	  
	  	  
	  	  

	 5.
	  	$	  		  	
	  
	  	  
	  	  
	  	  

 I certify that this report is accurate and complete:
                                         
                                         
               
 Description of Milestone Activities: 

Please return one copy of this form along with your report to the following address: 

The Ohio State University 
 Attn: Compliance 

Technology Commercialization Office 
 1524 North High Street 

Columbus, OH 43201 
 If you have questions, please call (614) 292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance@osu.edu. Thank you for your prompt attention. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	18	  	

 Appendix 1B 

OSIF ANNUAL REPORT 
  

			
	
Licensee:                        
                                         
                       

Inventor:                        
                                         
                        
 Period
Covered
From:                                        
                           

Prepared
By:                                        
                                         
 
 Approved
By:                                        
                                        

	  	 Agreement
No:                                        
                                    

OSIF’s Tech ID
No:                                        
                            

Through:                        
                                         
                     

Date:                         
                                         
                          

Date:                         
                                         
                          

  

	
	ANNUAL REPORT FOR THE PERIOD

 An annual report is due on
                                     covering the status of
all patent prosecution, commercial development, and licensing activities relating to the invention(s) covered by the above Agreement. (Please refer to the Agreement paragraph
                            ). 

 

							
	  

OSIF Tech ID No.
                                         
                                   

 
	  	 
	 Government regulations (Bayh-Dole) require reporting of any request to waive standard U.S. manufacturing requirements. Have you
requested such a waiver from a government agency?
 ☐
  Yes        ☐   No

	
	 If yes, please attach additional information and give the agency name, date requested,
and/or date granted.
  

	  
 Submitted
By:                                        

  

Title:                         
                               

 

Email:                         
                           
  
	  	
Date:                      
                  
  

Phone:                         
           

 Please return one copy of this form along with your report to the following address: 

The Ohio State University 
 Attn: Compliance 

Technology Commercialization Office 
 1524 North High Street 

Columbus, OH 43201 
 If you have questions, please call (614) 292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance@osu.edu. Thank you for your prompt attention. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	19	  	

 Appendix 1B 

OSIF ANNUAL REPORT 
 For
the Period:                              

 

					
	Patent Activity
	
	License/Sublicense Activity
	
	Description of Commercial Development (see attached form)
	
	 Description of any
Management Changes

	Title	  	Name	  	Since (Date)
	CEO	  		  	
	COO	  		  	
	CFO	  		  	
	CTO/CMO	  		  	

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	20	  	

 Appendix 1B 

OSIF ANNUAL REPORT 
 For
the Period:                                  

 

	
	Description of any Key Other Events

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	21	  	

 Appendix 1B 

OSIF ANNUAL REPORT 
 For
the Period:                          

OSIF COMMERCIAL DEVELOPMENT FORM 
 Please
select the type of product in development, check its current state of development, and completed the fields for the other information in the box. If you have additional information, please attach it to the end of this form. 

 

							
	 Therapeutic Products
 ☐
Discovery
 ☐ Pre-Clinical

☐ Phase 1 Clinical Trials
 ☐ Phase II Clinical
Trials
 ☐ Phase III Clinical Trials
 ☐ NDA
Submitted
 ☐ Selling Licensed Products
 ☐ Other:
                            
	 	 Date

                        

                        

                        

                        

                        

                        

                        

                        

	  	 Hardware/Engineering Products
 ☐
Research
 ☐ Functioning Prototype
 ☐ Beta
Testing
 ☐ Pilot Manufacturing Run
 ☐ Safety
Tested
 ☐ Selling Licensed Products
 ☐ Other:
                            
	  	 Date

                        

                        

                        

                        

                        

                        

                        

	 Drug in Development (brand name, if applicable):

                          
                                         
                                 

Therapeutic
Indication:                                       
                       
	  	 Product in Development (brand name, if applicable):

                          
                                         
                                  

Market
Addressed:                                       
                               

		 		  		  	
	 Software
 ☐ In Development

☐ Alpha Testing
 ☐ Beta Testing

☐ Selling Licensed Products
 ☐ Other:
                            
	 	 Date

                        

                        

                        

                        

                        

	  	 Copyright/Trademarked Products
 ☐
Functioning Prototype
 ☐ Alpha Testing
 ☐ Beta
Testing
 ☐ Selling Licensed Products
 ☐ Other:
                            
	  	 Date

                        

                        

                        

                        

                        

	 Tool in Development (brand name, if applicable):

Application:
	  	 Product in Development (brand name, if applicable):

Market Addressed:

				
	 Plant Products
 ☐ Discovery

☐ Gvt. Approval Applied For
 ☐ Gvt. Approval
Received
 ☐ Selling Licensed Products
 ☐ Other:
                            
	 	 Date

                        

                        

                        

                        

                        

	  	 Medical Devices/Diagnostics
 ☐
Research
 ☐ Pre-Clinical

☐ 510(k)/CE Mark Submitted
 ☐ PMA

☐ Selling Licensed Products
	  	 Date

                        

                        

                        

                        

                        

	Product in Development (brand name, if applicable):	  	☐ Other:                             	  	                        
	
                          
                                         
                                       

Field of Product:
                                         
                                     
	  	 Device/Diagnostic in Development (brand name, if applicable):

                          
                                         
                                 

Medical Field:
                                         
                                   

		
	 Please return one copy of this form along with your report to

the following address:
 Ohio State Innovation Foundation

Attn: Compliance
 Technology Commercialization Office

1524 North High Street
 Columbus, OH 43201
	  	If you have questions, please call (614) 292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to
tcocompliance@osu.edu. Thank you for your prompt attention.

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	22	  	

 Appendix 1C 

OSIF QUARTERLY REPORT 
  

			
	
Licensee:                        
                                         
                   

Inventor:                        
                                         
                   
 Period Covered
From:                                        
                       
 Prepared
By:                                        
                                      

Approved
By:                                        
                                    
	  	 Agreement
No:                                        
                            

OSIF’s Tech ID
No:                                        
                    

Through:                        
                                         
             

Date:                         
                                         
                  

Date:                         
                                         
                  

	
	If license covers several major product lines, please prepare a separate report for each line. Then combine all product lines into a summary report.

 Report Type: 
  

					
	☐ Single Product Line
Report:                                        
                                         
                                         
                          
	☐ Multiproduct Summary
Report:                                        
                                         
                                         
                  
		  	 Page 1 of          pages
	  	 Trade Name:
                                        

	Product Line Details:	  	Line:                                     
                   	  	Pages:
                                      

  

																	
	Report Currency:	  	☐ U.S. Dollars 	  		  	☐ Other:
	  	  	Country	  	Gross
Consideration	  	Allowances	  	Net
Sales1	  	Royalty
Rate	  	Royalty
Amount	  	Royalty
Paid
Last
Year	  	Next 
Year
Royalty
Forecast2
	1. Total Q1	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	2. Total Q2	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	3. Total Q3	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	4. Total Q4___	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	5. Total FY_	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	6. Minimum Annual Royalty	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	7. Annual Royalty3 for FY	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	8. Amount Paid-to-Date4	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	9. Amount Payable5	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 

  

					
	Total Royalty:                         	  	Conversion Rate:                         	  	Royalty in U.S. Dollars:                         
	
	 1means the Gross Consideration paid to, received by, or given to
Licensee, Affiliates, and Sublicensees from the Sale of Licensed Products and Licensed Processes, less the following items directly attributable to the Sale of such Licensed Products that are specifically identified on the invoice for such Sale and
borne by the Licensee, Affiliates, or Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding income taxes; (c) import and
export duties actually paid; (d) freight, transport, packing and transit insurance charges actually paid or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the original
invoiced amount.
 2The royalty forecast is non-binding and is
for OSIF’s internal planning purposes only
 3(greater of line 5 or 6)

4(lines 1+2+3)

5(line 7-line 8)

  

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	23	  	

 Appendix 1C 

OSIF QUARTERLY REPORT 
  

			
	 Any other consideration due OSIF during this Royalty Period:
	  	
	
Milestones:                 
                           
	  	
	Minimum Royalties:                            	  	Sublicense
Payments:                                    
	
	On a separate page, please indicate the reason for returns or adjustments if significant. Also note any unusual occurrences that affect royalty amounts during this period. To assist OSIF’s forecasting, please
comment on any significant expected trends in sales volume.
	
	 I certify that this report is accurate and
complete:                                       
                             

 Please return one copy of this form along with your report to the following address: 

The Ohio State University 
 Attn: Compliance 

Technology Commercialization Office 
 1524 North High Street 

Columbus, OH 43201 
 If you have questions, please call (614) 292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance@osu.edu. Thank you for your prompt attention. 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	24	  	

 Appendix 2 

LICENSEE’S AFFILIATES 

  

					
			
	{00245154-1} Licensee: Cellectis	  	CONFIDENTIAL	  	Exclusive License (Life Sciences)
	 Licensor: Ohio State Innoation Foundation A2014-1834 // CLS-14086
	  	
	 NYI-524635066v1
	  		  	
		  	25EX-4.25

					
	Confidential	  	 	Exhibit 4.25	 

  
 CONFIDENTIAL
TREATMENT REQUESTED BY CELLECTIS S.A. 
 LICENSE AGREEMENT 

This License Agreement (the “Agreement”) is entered into as of March 8, 2019 (the “Effective Date”), by
and among Allogene Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 210 East Grand Avenue, South San Francisco, California, 94080
(“Allogene”) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Allogene and Cellectis may
each be referred to herein individually as a “Party” and collectively as the “Parties.” 
 WHEREAS,
Cellectis and Pfizer, Inc. (“Pfizer”) entered into a Research Collaboration and License Agreement dated as of June 17, 2014, as amended on December 1, 2016 (the “Research Collaboration and License
Agreement”) pursuant to which Cellectis and Pfizer performed certain research services (“Research Plan Services”) according to a defined program (the “Research Program”) and a defined plan (the “Research Plan”)
in connection with a research collaboration during the period from June 18, 2014 to June 17, 2018 (the “Research Term”), and each of Cellectis and Pfizer granted to each other certain licenses and other rights to develop and
commercialize specified CAR-T products. 
 WHEREAS, in connection with the sale by Pfizer to
Allogene, of certain assets to which the Research Collaboration and License Agreement relates, Pfizer has assigned the Research Collaboration and License Agreement to Allogene effective as of April 6, 2018 (the “Assignment”).

 WHEREAS, as the Research Plan Services have been completed and the Research Term has expired (both under the Research
Collaboration and License Agreement), Allogene and Cellectis have terminated the Research Collaboration and License Agreement. 

WHEREAS, notwithstanding such termination, Allogene and Cellectis desire to execute this Agreement, to reflect the ongoing relationship
between Cellectis and Allogene, pursuant to which each of Allogene and Cellectis will grant licenses and other rights to the other Party, including certain intellectual property rights that arose as a result of the Research Plan Services, in each
case as further set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 DEFINITIONS. 

When used in this Agreement, the following capitalized terms will have the meanings set forth in this Article 1. Any terms defined
elsewhere in this Agreement will be given equal weight and importance as though set forth in Article 1. 

  
 1 

 Confidential 
  

 1.1.    “Additional Third Party Licenses” is defined in
Section 5.2.2(b). 
 1.2.    “Affiliate” means, with respect to any Person, any other Person that
controls, is controlled by or is under common control with such Person. A Person will be regarded as in control of another entity if it owns or controls at least fifty percent (50%) of the equity securities of the subject entity entitled to vote in
the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority), provided, however, that the term “Affiliate” will not include subsidiaries or other entities in
which a Party or its Affiliates owns a majority of the ordinary voting power necessary to elect a majority of the board of directors or other managing authority, but is restricted from electing such majority by contract or otherwise, until such time
as such restrictions are no longer in effect. 
 1.3.    “Agreement” is defined in the introduction to
this Agreement. 
 1.4.    “Agreement CAR-T” means any CAR-T utilizing the Cellectis Technology that is identified, created or developed Targeting an Allogene Target. 

1.5.    “Alliance Manager” is defined in Section 2.3. 

1.6.    “Allogene CAR-T Developed IP” [***] 

1.7.    “Allogene Diligence Obligation” is defined in Section 2.2.3. 

1.8.    “Allogene Improvements” [***] 

1.9.    “Allogene Indemnified Party” is defined in Section 10.3. 

1.10.    “Allogene Know-How” means any Know-How comprised in the Allogene Technology. 
 1.11.    “Allogene Licensed
Product” means any product containing an Agreement CAR-T that is claimed or covered by, or was made using or otherwise incorporates, any Licensed Cellectis Intellectual Property. 

1.12.    “Allogene Patent Right” means any Patent Right comprised in the Allogene Technology. 

1.13.    “Allogene Target” means each of the Targets listed on Schedule 1.13 of
this Agreement. 
 1.14.    “Allogene Technology” [***] 

1.15.    “Annual Net Sales” means, with respect to any Allogene Licensed Product in a Calendar Year during
the applicable Royalty Term for such Allogene Licensed Product, the aggregate Net Sales by Allogene, its Affiliates and its Sublicensees from the sale of such Allogene Licensed Product in the Territory during such Calendar Year. 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 2 

 Confidential 
  

 1.16.    “Applicable Law” means the laws, statutes,
rules, regulations, guidelines, or other requirements that may be in effect from time to time and apply to a Party’s activities to be performed under this Agreement, including any such laws, statutes, rules, regulations, guidelines, or other
requirements of the FDA or the EMA. 
 1.17.    “Applicable Allogene Technology” means any (a) Know-How Controlled by Allogene or its Affiliates that was invented, discovered or developed during the term of the Research Collaboration and License Agreement or the Term and in connection with
Allogene’s (or Pfizer’s or its Affiliates’, prior to the Assignment) or its Affiliates’ activities under the Research Collaboration and License Agreement or this Agreement and (b) Patent Rights Controlled by Allogene or its
Affiliates as of the date of termination of the Research Term, to the extent that such Patent Right claims any Know-How described in clause (a) above, to the extent that such Know-How and Patent Rights are necessary for the further development, manufacture and commercialization of Continuation Products. 

1.18.    “Binding Obligation” means, with respect to a Party (a) any oral or written agreement or
arrangement that binds or affects such Party’s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement; (b) the provisions of such Party’s charter, bylaws or other
organizational documents or (c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party’s operations or property are bound. 

1.19.    “Biosimilar Biologic Product” is defined in Section 5.2.2(a). 

1.20.    “Biosimilar Notice” means a copy of any application submitted by a Third Party to the FDA under
42 U.S.C. § 262(k) of the PHS Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biological product, which application identifies an Allogene Licensed Product as the
reference product with respect to such product, and other information that describes the process or processes used to manufacture the biological product. 

1.21.    “BLA” means a Biologics License Application filed with the FDA in the United States with respect
to a Licensed Product, as defined in Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et. seq. 

1.22.    “Business Day” means a day other than a Saturday, a Sunday or a day that is a national holiday in
the United States. 
 1.23.    “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.24.    “Calendar Year” means each successive period of twelve (12) calendar months commencing on
January 1 and ending on December 31. 

  
 3 

 Confidential 
  

 1.25.    “CAR” means a chimeric antigen receptor
expressed from an experimentally validated Cellectis viral construct with specific molecular architecture and signaling domain sequences. 

1.26.    “CAR-T” means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using Cellectis Technology. 

1.27.    “Cellectis CAR-T Developed IP” means
Developed IP directed to the manufacture, composition or use of CAR-Ts Targeting a Cellectis Program Target. 

1.28.    “Cellectis Improvement” [***] 

1.29.    “Cellectis Indemnified Party” is defined in Section 10.2. 

1.30.    “Cellectis Insolvency Event” means the occurrence of any of the following: (a) a case is
commenced by or against Cellectis under applicable bankruptcy, insolvency or similar laws, (b) Cellectis files for or is subject to the institution of bankruptcy, reorganization, liquidation, receivership or similar proceedings,
(c) Cellectis assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for Cellectis’ business, (e) a substantial portion of Cellectis’ business is subject to
attachment or similar process, (f) Cellectis suspends or threatens to suspend making payments with respect to all or any class of its debts or (g) anything analogous to any of the events described in the foregoing clauses (a) through
(f) occurs under the laws of any applicable jurisdiction. 
 1.31.    “Cellectis
Know-How” means any Know-How comprised in the Cellectis Technology that was introduced into the Research Program by Cellectis pursuant to the applicable
Research Plan under the Research Collaboration and License Agreement. 
 1.32.    “Cellectis Patent
Right” means any Patent Right comprised in the Cellectis Technology. The Cellectis Patent Rights existing as of June 17, 2014 include those set forth on Schedule 1.32 attached hereto. 

1.33.    “Cellectis Product” means any product incorporating a
CAR-T Targeting a Cellectis Program Target which would infringe a Valid Claim of any Licensed Allogene Intellectual Property in the absence of the Licenses from Allogene pursuant to Section 4.2 or that is
claimed or covered by, or was made using or otherwise incorporates, any Allogene Intellectual Property or Developed IP. 

1.34.    “Cellectis Program Target” means the Targets listed in Schedule 1.34. 

1.35.    “Cellectis Technology” [***] 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 4 

 Confidential 
  

 1.36.    “Cellectis Third Party Agreement” means any
agreement between Cellectis and any Third Party under which Cellectis obtains rights in or to any Cellectis Licensed Intellectual Property. 

1.37.    “Change of Control” means, with respect to a Party, (a) a merger, reorganization or
consolidation of such Party with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty (50%) of the combined voting power of the surviving entity immediately
after such merger, reorganization or consolidation, (b) a Third Party becoming the beneficial owner of fifty (50%) or more of the combined voting power of the outstanding securities of such Party or (c) the sale or other transfer to a
Third Party of all or substantially all of such Party’s business or assets to which this Agreement relates. 

1.38.    “Combination Product” means an Allogene Licensed Product containing an Agreement CAR-T and one or more other therapeutically active ingredients. 

1.39.    “Commercialization” or “Commercialize” means activities directed to marketing,
promoting, distributing, importing, exporting, using for commercial purposes or selling or having sold an Allogene Licensed Product. Commercialization will not include any activities related to Manufacturing or Development. 

1.40.    “Commercially Reasonable Efforts” [***] 

1.41.    “Confidential Information” of a Party means all Know-How
or other information, including proprietary information and materials (whether or not patentable) regarding such Party’s technology, products, business or objectives, that is communicated in any way or form by the Disclosing Party to the
Receiving Party, either prior to or after the Effective Date of this Agreement (including any information disclosed pursuant to the Research Collaboration and License Agreement), and whether or not such
Know-How or other information is identified as confidential at the time of disclosure. The terms and conditions of this Agreement will be deemed to be the Confidential Information of each Party. Cellectis
Improvements will be deemed to be the Confidential Information of Cellectis. Allogene Improvements will be deemed to be the Confidential Information of Allogene. Developed IP will be deemed to be the Confidential Information of each Party, except
that Allogene CAR-T Developed IP is deemed to be the Confidential Information solely of Allogene, and Cellectis CAR-T Developed IP is deemed to be Confidential
Information solely of Cellectis. For clarity, any Pfizer Confidential Information under the Research Collaboration and License Agreement shall be considered Allogene Confidential Information under this Agreement. Any Cellectis Confidential
Information provided to Pfizer under the Research Collaboration and License Agreement shall be considered Cellectis Confidential Information under this Agreement. 

1.42.    “Continuation Product” is defined in Section 9.6.3(c). 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 5 

 Confidential 
  

 1.43.     “Control” or “Controlled”
means, with respect to any (a) item of information, including Know-How, or (b) intellectual property right, the possession (whether by ownership interest or license, other than pursuant to this
Agreement) by a Party of the ability to grant to the other Party access to or a license under such item or right, as provided herein, without violating the terms of any agreement or other arrangements with any Third Party. 

1.44.    “Develop” or “Development” means to discover, research or otherwise develop a
product, including conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology,
pharmacology and other similar efforts, test method development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis,
clinical studies (including pre- and post-approval studies), development of diagnostic assays in connection with clinical studies, and all activities directed to obtaining any Regulatory Approval, including
any marketing, pricing or reimbursement approval. 
 1.45.    “Developed IP” [***] 

1.46.    “Development Milestone” is defined in Section 5.1.1. 

1.47.    “Development Milestone Payment” is defined in Section 5.1.1. 

1.48.    “Diligence Issue” is defined in Section 2.2.4. 

1.49.    “Disclosing Party” is defined in Section 7.1. 

1.50.    “Effective Date” is defined in the introduction to this Agreement. 

1.51.    “EMA” means the European Medicines Agency, or any successor agency thereto. 

1.52.    “Escalation Process” is defined in Section 11.11. 

1.53.     “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C.
§ 301 et seq.), as amended, and the rules and regulations promulgated thereunder. 
 1.54.    “FDA”
means the United States Food and Drug Administration or any successor agency thereto. 

1.55.    “Field” means human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. 

1.56.    “First Commercial Sale” means, with respect to any Allogene Licensed Product and any country of
the world, the first sale of such Allogene Licensed Product under this Agreement by Allogene, its Affiliates or its Sublicensees to a Third Party in such country, after such Allogene Licensed Product has been granted Regulatory Approval by the
competent Regulatory Authorities in such country. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 6 

 Confidential 
  

 
1.57.    “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.58.    “Generic Competition” is defined in Section 5.2.2(a). 

1.59.    “Governmental Authority” means any court, agency, department, authority or other instrumentality
of any national, state, county, city or other political subdivision. 
 1.60.    “ICC” is defined in
Section 11.12. 
 1.61.    “IND” means an Investigational New Drug Application, as defined in the
FD&C Act, that is required to be filed with the FDA before beginning clinical testing of an Allogene Licensed Product or Cellectis Product, as applicable, in human subjects, or an equivalent foreign filing. 

1.62.    “Indemnified Party” is defined in Section 10.4.1. 

1.63.    “Indemnifying Party” is defined in Section 10.4.1. 

1.64.    “Joint Developed IP” is defined in Section 6.1.1(c). 

1.65.    “Joint Patent Right” is defined in Section 6.2.1(d). 

1.66.     “Know-How” means any proprietary invention, discovery,
data, information, process, method, technique, material, technology, result or other know-how, whether or not patentable. 

1.67.    “Law” means any law, statute, rule, regulation, order, judgment or ordinance of any Governmental
Authority. 
 1.68.    “Liability” is defined in Section 10.2. 

1.69.    “License” is defined in Section 4.1.1. 

1.70.    “Licensed Cellectis Intellectual Property” means any and all intellectual property (including
Patent Rights and Know-How) Controlled by Cellectis, including the Cellectis Technology, the Cellectis Improvements and Cellectis’ interest in the Developed IP, for Allogene to make, have made, use, have
used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Allogene Licensed Products. 

1.71.    “Licensed Allogene Intellectual Property” means any and all Allogene Technology, Allogene
Improvement, and Allogene’s interest in the Developed IP, for Cellectis to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Cellectis
Products. 

  
 7 

 Confidential 
  

 1.72.    “Litigation Conditions” is defined in
Section 10.4.2. 
 1.73.    “MAA” means an application with the EMA seeking Regulatory Approval of
a Licensed Product in Europe using the EMA’s centralized procedure. 
 1.74.    “Major EU Market
Country” means any of [***]. 
 1.75.    “Major Market Country” means any Major EU Market
Country, [***]. 
 1.76.    “Manufacturing” or “Manufacture” means activities directed
to making, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping or storage of a product. 

1.77.    “Marginal Royalty Rates” is defined in Section 5.2. 

1.78.    [***] 

1.79.    “Misuse” means any use of Cellectis Confidential Information or
Know-How by Allogene in violation of Allogene’s non-use obligations pursuant to this Agreement or outside the scope of the licenses granted hereunder. For the
avoidance of doubt, “Misuse” will not include Allogene’s disclosure of Cellectis Confidential Information to any Third Party in violation of Article 7. 

1.80.    “Misuse Allegation” is defined in Section 11.11. 

1.81.    “Most Advanced Targets” is defined in Section 2.2.5. 

1.82.    “Necessary” is defined in Section 5.2.2(b). 

1.83.    “Net Sales” [***] 

  1.83.1.    [***] 

  1.83.2.    [***] 

  1.83.3.    [***] 

1.84.    “Non-Disclosing Party” is defined in Section 7.3.2.

 1.85.    “Notice of Dispute” is defined in Section 11.10.1. 

1.86.    “Other Cellectis Target” means the Targets listed in
Schedule 1.86. 
 1.87.    “Other Field” means anti-tumor adoptive
immunotherapy. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 8 

 Confidential 
  

 1.88.    “Other Products” [***] 

1.89.    “Other Territory” means the United States of America together with any additional territories as
amended from time to time by Cellectis at the written direction of Servier pursuant to the Servier Agreement. 

1.90.     “Party” and “Parties” is defined in the introduction to this Agreement. 

1.91.    “Patent Rights” means any and all (a) patents, (b) pending patent applications, including
all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term extensions,
supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) any other form of government-issued right substantially similar to any of the foregoing and (f) all United States and foreign
counterparts of any of the foregoing. The Patent Rights owned by either Party include any Patent Right assigned to such Party pursuant to the provisions of this Agreement. 

1.92.    “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or
agency of a government. 
 1.93.    “Phase I Clinical Trial” means a study of an Allogene Licensed
Product in human subjects or patients with the endpoint of determining initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R.
§ 312.21(a), or its successor regulation, or the equivalent regulation in any other country. A so-called Phase I/II Clinical Trial will be deemed to be a Phase I Clinical Trial unless such study, when
completed, allows Allogene to proceed directly to a Phase III Clinical Trial. 
 1.94.    “Phase II Clinical
Trial” means a study of an Allogene Licensed Product in human patients to determine the safe and effective dose range in a proposed therapeutic indication as and to the extent defined for the United Sates in 21 C.F.R. § 312.21(b), or
its successor regulation, or the equivalent regulation in any other country. 
 1.95.    “Phase III Clinical
Trial” means a study of an Allogene Licensed Product in human patients with a defined dose or a set of defined doses of an Allogene Licensed Product designed to (a) ascertain efficacy and safety of such Allogene Licensed Product for
its intended use; (b) define warnings, precautions and adverse reactions that are associated with the Allogene Licensed Product in the dosage range to be prescribed; and (c) support preparing and submitting applications for Regulatory
Approval to the competent Regulatory Authorities in a country of the world, as and to the extent defined for the United States in 21 C.F.R.§ 312.21(c), or its successor regulation, or the equivalent regulation in any other country. 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 9 

 Confidential 
  

 1.96.    “PHS Act” means the United States Public Health
Service Act, as amended, and the rules and regulations promulgated thereunder. 
 1.97.    “Price
Approval” means, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination
effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be) 

1.98.    “Receiving Party” is defined in Section 7.1. 

1.99.    “Regulatory Approval” means all technical, medical and scientific licenses, registrations,
authorizations and approvals (including approvals of BLAs, MAAs, supplements and amendments, pre- and post- approvals, pricing and Third Party reimbursement approvals, and labeling approvals) of any Regulatory
Authority, necessary for the use, Development, Manufacture and Commercialization of a pharmaceutical product in a regulatory jurisdiction. For the sake of clarity, Regulatory Approval will not be achieved for an Allogene Licensed Product in a
country until all applicable Price Approvals have also been obtained by Allogene, its Affiliates, sublicensees or distributors, where applicable, for such Allogene Licensed Product in such country. 

1.100.    “Regulatory Approval Application” means any application submitted to an appropriate Regulatory
Authority seeking any Regulatory Approval. 
 1.101.    “Regulatory Authority” means, with respect to
any national, supra-national, regional, state or local regulatory jurisdiction, any agency, department, bureau, commission, council or other governmental entity involved in the granting of a Regulatory Approval for such jurisdiction. 

1.102.    “Representative” is defined in Section 7.2.1. 

1.103.    “Research Collaboration and License Agreement” is defined in the introduction to this Agreement.

 1.104.     “Research Plan” is defined in the introduction of this Agreement. 

1.105.    “Research Plan Services” is defined in the introduction of this Agreement. 

1.106.    “Research Program” is defined in the introduction of this Agreement. 

1.107.    “Research Term” is defined in the introduction of this Agreement. 

1.108.    “Royalty Term” means, on an Allogene Licensed Product-by-Allogene Licensed Product and country-by-country basis, the period of time from the First Commercial Sale of such
Allogene Licensed Product in such country until the later of (i) the expiration of 

  
 10 

 Confidential 
  

 
the last Valid Claim that would, but for the license to or ownership by Allogene hereunder, be infringed by the sale of such Allogene Licensed Product in such country; (ii) the loss of
regulatory exclusivity for the Allogene Licensed Product in such country or (iii) the tenth (10th) anniversary of the date of the First Commercial Sale of such Allogene Licensed Product in
such country, but in no event later than the twentieth (20th) anniversary of the date of the First Commercial Sale in any country. 

1.109.    “Rules” is defined in Section 11.12. 

1.110.    “Sales Milestone” is defined in Section 5.1.2. 

1.111.    “Sales Milestone Payment” is defined in Section 5.1.2. 

1.112.    “Sales Threshold” is defined in Section 5.1.2. 

1.113.    “SEC” means the United States Securities and Exchange Commission. 

1.114.    “Servier” means Les Laboratoires Servier, a corporation organized and existing
under the laws of France and having a place of business located at 50 rue Carnot, 92150 Suresnes, France. 

1.115.    “Servier Agreement” means that certain Research, Product Development, Option, License and
Commercialization Agreement by and between Servier and Cellectis dated February 7, 2014, as amended and terminated; and the License, Development, Option, and Commercialization Agreement by and between Servier and Cellectis dated March 6,
2019. 
 1.116.    “Sublicensee” means any Person to whom Allogene grants or has granted, directly or
indirectly, a sublicense of rights licensed by Cellectis to Allogene under this Agreement, in accordance with the provisions of this Agreement. 

1.117.    “[***] Patent Rights” means the Patent Rights set forth on Schedule 9.23 under the
headings: CELLECTIS Patent Portfolio on [***], In-licensed Patent applications from [***], In-Licensed patent applications from [***],
In-Licensed Patent applications from [***] and In-Licensed Patent Rights from [***]. The value attributed to the [***] Patent Rights corresponds to [***] of the total
value of the Cellectis Technology. 
 1.118.    “Target” means (a) a specific biological molecule
that is identified by a GenBank accession number or similar information, or by its amino acid or nucleic acid sequence, and (b) any biological molecule substantially similar in amino acid or nucleic acid sequence that has substantially the same
biological function as a molecule disclosed in clause (a), including any naturally occurring mutant or allelic variant of a molecule disclosed in clause (a), including naturally occurring variants, mutants, transcriptional and post-transcriptional
isoforms (e.g., alternative splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c) truncated forms (including fragments thereof) which have a biological function
substantially similar to that of any biological molecules disclosed in clause (a) or clause (b). 

  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 11 

 Confidential 
  

 1.119.    “Targeting” means, when used to describe the
relationship between a molecule and a Target, that the molecule (a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part through binding to such Target (or
such portion thereof). 
 1.120.    “Term” is defined in Section 9.2. 

1.121.    “Terminated Allogene Licensed Product” is defined in Section 9.6.1(a). 

1.122.    “Terminated Target” is defined in Section 9.6.1. 

1.123.    “Territory” means the entire world. 

1.124.    “Third Party” means any Person other than Allogene, Cellectis or their respective Affiliates.

 1.125.    “Third Party Claim” is defined in Section 10.4.1. 

1.126.    “Trademark” means any trademark, trade dress, design, logo, slogan, house mark or name used in
connection with the Commercialization of any Allogene Licensed Product by Allogene or its Affiliates or Sublicensees hereunder, including any registration or application for registration of any of the foregoing. 

1.127.    “Useful” is defined in Section 5.2.2(b). 

1.128.    “Valid Claim” means, with respect to a particular country, a claim of an issued and unexpired
patent right included within the Licensed Intellectual Property or Developed IP that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental authority of competent jurisdiction, which
decision is unappealed or unappealable within the time allowed for appeal, and (ii) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. An Allogene
Licensed Product is “Covered” by a Valid Claim if its referenced activity by Allogene or its Sublicensees would, but for the licenses granted by Cellectis under this Agreement, infringe such Valid Claim. 

1.129.    Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein
will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” will be
deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference to any agreement,
instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein”, “hereof” and “hereunder”, and words of similar
import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to sections or exhibits will be 

  
 12 

 Confidential 
  

 
construed to refer to sections or exhibits of this Agreement, and references to this Agreement include all exhibits hereto, (h) the word “notice” means notice in writing (whether
or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,”
“consent” or “approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement
or successor law, rule or regulation thereof, (k) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), and (l) the term “or” will be interpreted in the inclusive sense commonly associated with the term
“and/or.” 
  

	2.	 EXCLUSIVITY AND DILIGENCE OBLIGATIONS. 

2.1.    Exclusivity. Subject to Sections 2.2.5, 4.1.2(e) and 4.5, during the Term of this Agreement, for each
Allogene Target, neither Cellectis nor any of its Affiliates will (a) grant, or seek to grant, any right under any Cellectis Technology, Cellectis Improvements, Allogene Improvements licensed to Cellectis pursuant to Section 4.2.2 or
Developed IP to any Third Party with respect to such Allogene Target or (b) use any Cellectis Technology, Cellectis Improvements, Allogene Improvements licensed to Cellectis pursuant to Section 4.2.2 or Developed IP to Develop (itself or
through or with a Third Party) or Commercialize CAR-Ts Targeting such Allogene Target. 
  

	 	2.2.    Diligence.	 

2.2.1.    Allogene Development Diligence. Allogene will use Commercially Reasonable Efforts to Develop [***] for
[***] during the Term. For avoidance of doubt, any actions taken by Allogene’s Affiliates or Sublicensees under this Agreement will be treated as actions taken by Allogene in regard to satisfaction of the requirements of this
Section 2.2.1. 
 2.2.2.    Commercial Diligence. Allogene will use Commercially Reasonable Efforts to
Commercialize [***] where Allogene has received Regulatory Approval for [***] in such country. Allogene will have no other diligence obligations with respect to the Commercialization of Allogene Licensed Products under this Agreement. For avoidance
of doubt, any actions taken by Allogene’s Affiliates or Sublicensees under this Agreement will be treated as actions taken by Allogene in regard to satisfaction of the requirements of this Section 2.2.2. 

2.2.3.    Exceptions to Diligence Obligations. Notwithstanding any provision of this Agreement to the contrary,
Allogene will be relieved from and will have no 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 13 

 Confidential 
  

 
obligation to undertake any efforts with respect to any diligence obligation under each of the Allogene Targets pursuant to Section 2.2.1 or Section 2.2.2 (each, an “Allogene
Diligence Obligation”) in the event that: 
 (a)    Allogene receives or generates any safety, tolerability or
other data reasonably indicating or signaling, as measured by Allogene’s safety and efficacy evaluation criteria and methodology, that such Allogene Licensed Product has or would have an unacceptable risk-benefit profile or is otherwise not
reasonably suitable for initiation or continuation of clinical trials in humans; 
 (b)    Allogene receives any
notice, information or correspondence from any applicable Regulatory Authority, or any applicable Regulatory Authority takes any action, that reasonably indicates that such Allogene Licensed Product is unlikely to receive Regulatory Approval; or

 (c)    the Allogene Diligence Obligation breach related to such Allogene Target is caused by the negligence,
recklessness or intentional acts of Cellectis. 
 2.2.4.    Assertion of Diligence Obligation Claims. If Cellectis
is, becomes, or reasonably should be aware of facts that might form a reasonable basis that Allogene has failed to meet its Diligence Obligation then Cellectis will promptly notify Allogene in writing of such potential alleged performance failure
(each such potential alleged performance failure, a “Diligence Issue”). Promptly upon Allogene’s receipt of any notice of a Diligence Issue pursuant to this Section 2.2.4, the Allogene Alliance Manager and Cellectis
Alliance Manager will meet to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than [***] after receipt of such a notice, (a) the Parties have not
reached consensus regarding whether Allogene has failed to satisfy the Allogene Diligence Obligations and (b) the Parties’ respective Alliance Managers have not agreed upon an appropriate corrective course of action for such Diligence
Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 11.10. If Cellectis fails to notify Allogene of a Diligence Issue pursuant to this Section 2.2.4 within
[***] after the date that Cellectis first discovers or reasonably should have discovered such Diligence Issue, then Allogene will be deemed to have satisfied its Diligence Obligations, with respect to such Diligence Issue.

2.2.5.    Remedies for Breach of Allogene Diligence Obligations. Subject to Section 2.2.3(c), if Allogene
materially breaches any Allogene Diligence Obligation and fails to remedy such breach within ninety (90) days of Allogene’s receipt of notice of such breach from Cellectis, then, with respect [***] Allogene Targets, [***] will cease to be
an Allogene Target and will become a Cellectis Program Target and with respect to any Allogene Targets other than [***], the applicable Allogene Target(s) will no longer be subject to the exclusivity provisions set forth in Section 2.1 above.

  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 14 

 Confidential 
  

 2.3.    Alliance Manager. Each of the Parties will appoint a
single individual to serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager will be to facilitate the relationship between the Parties as established by this Agreement. 

 

	3.	 PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS. 

3.1.    General. As of and from the Effective Date, Allogene will have sole authority over and control of the
Development, Manufacture and Commercialization of Allogene Licensed Products Targeting such Allogene Target. 

3.2.    Regulatory Approvals. Allogene or its designated Affiliate(s) will file, in its own name, all
Regulatory Approval applications for Allogene Licensed Products Targeting such Allogene Target where Allogene, in its sole discretion, determines it is commercially advantageous to do so. Allogene, or its designated Affiliate(s), will have the sole
responsibility for, and sole authority with respect to, communications with any Regulatory Authority regarding any Regulatory Approval Application or any Regulatory Approval for an Allogene Licensed Product once granted. Except to the extent
necessary to fulfill its obligations under Section 2.2.1, neither Allogene nor any of its Affiliates will have any obligation to seek Regulatory Approval for any Allogene Licensed Product. 

 

	 	3.3.    Control	 of Commercialization Activities. 

3.3.1.    General. For each Allogene Target, Allogene will have sole and exclusive control over all matters
relating to the Commercialization of Allogene Licensed Products Targeting such Allogene Target; and 

3.3.2.    Trademarks. Allogene will select and own all Trademarks used in connection with the
Commercialization of any such Allogene Licensed Products, including all goodwill associated therewith. Neither Cellectis nor its Affiliates will use or seek to register, anywhere in the world, any trademarks which are confusingly similar to any
Trademarks used by or on behalf of Allogene, its Affiliates or Sublicensees in connection with any Allogene Licensed Product. Nothing in this Section 3.3.2 will be construed to prevent Cellectis from granting Allogene any license or right in
and to any trademark, trade dress, design, logo, slogan, house mark or name Controlled by Cellectis. 

3.4.    Manufacturing. Allogene will have the exclusive right (subject to Sections 2.2.4 and 4.5) to
Manufacture Allogene Licensed Products Targeting such Allogene Target itself or through one or more Affiliates or Third Parties selected by Allogene. Allogene will have no diligence obligations with respect to the Manufacture of Allogene Licensed
Products except to the extent necessary to fulfill the Allogene Diligence Obligations. Allogene will be responsible for 100% of the associated costs for the manufacturing of Allogene Licensed Products. 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 15 

 Confidential 
  

 3.5.    Allogene Progress Reporting. Commencing on the Effective
Date and until delivery of the first royalty report pursuant to Section 5.4.2, Allogene will provide Cellectis with annual written reports on Allogene’s activities to Develop and Commercialize Allogene Licensed Products Targeting such
Allogene Target. Any information or written report provided by Allogene to Cellectis pursuant to this Section 3.5 will be deemed to be Allogene’s Confidential Information subject to the provisions of Article 7. 

 

	 	3.6.    Right	 of First Refusal. 

In the event that Cellectis proposes to enter into any Third Party agreement related to the Development or Commercialization of any CAR
Targeting a Cellectis Program Target (each a “Cellectis Target Product”) in the Field, Cellectis will first provide Allogene with written notice of such proposal, including all material terms and conditions thereof (each a
“Cellectis Target Product Notice”). For [***] following receipt of the Cellectis Target Product Notice, Allogene will have the option to purchase or license from Cellectis the Cellectis Target Product upon the terms and conditions
set forth in the Cellectis Target Product Notice. In the event Allogene elects to purchase or license the Cellectis Target Product from Cellectis, Allogene will give written notice of its election to Cellectis within such [***] and the Parties will
negotiate a mutually agreeable agreement for the purchase or license of the Cellectis Target Product within [***]; provided that the timeline for completing the agreement is not delayed by the actions or inactions of Cellectis. If Allogene does not
elect to purchase or license the Cellectis Target Product, Cellectis may, within [***] following the expiration of the option right granted to Allogene, transfer or license the Cellectis Target Product to the proposed transferee or any other
transferee, provided that this transfer will not be on terms and conditions more favorable to the transferee than those contained in the Cellectis Target Product Notice. In the event that Cellectis does not enter into the Third Party agreement to
which the Cellectis Target Product Notice relates, this Section 3.6 will continue to apply with respect to the Cellectis Product Target. This Section 3.6 will be applicable to any potential Third Party agreement that Cellectis proposes
entering into during the Term related to the Development or Commercialization of any CAR Targeting a Cellectis Program Target in the Field. 

3.7.    Right of Negotiation. In the event that Cellectis proposes to enter into any Third Party agreement related
to the Development or Commercialization of any product Targeting an Other Cellectis Target, Cellectis will provide Allogene with written notice of such intent and will negotiate in good faith with Allogene regarding Allogene’s purchase or
license of such product Targeting an Other Cellectis Target. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 16 

 Confidential 
  

	4.	 LICENSES AND RELATED GRANTS OF RIGHTS. 

 

	 	4.1.    Grants	 to Allogene. 

4.1.1.    Exclusive License. Subject to the terms and conditions of this Agreement, on an Allogene Target-by-Allogene Target basis, Cellectis hereby grants to Allogene and its Affiliates an exclusive (even as to Cellectis) license under the Licensed Cellectis Intellectual
Property (excluding [***] Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Allogene Licensed Products in the Field in the
Territory, with the right to sublicense as provided in Section 4.1.4 (the “License”). 

4.1.2.    [***] Patent Rights. 

(a)    Subject to the terms and conditions of this Agreement on an Allogene Target-by-Allogene Target basis, Cellectis hereby grants to Allogene and its Affiliates the right to use the [***] engineered by Cellectis to Develop Allogene Licensed Products until the filing of an IND for
each Allogene Licensed Product, in the Field. 
 (b)    Subject to the terms and conditions of this Agreement on an
Other Product-by-Other Product basis and effective as of October 30, 2015 (or such later date as such Other Product is included hereunder pursuant to the Servier
Agreement), Cellectis hereby grants to Allogene and its Affiliates the right to use the [***] engineered by Cellectis pursuant to the Servier Agreement to Develop Other Products, and Cellectis shall further have the obligation to grant the rights
set forth in this Section 4.l.2(b) to subcontractors as directed by Allogene pursuant to Section 4.l.5(b) herein, until the filing of an IND for each Other Product, in the Other Field. 

(c)    Subject to the terms and conditions of this Agreement, on an Allogene Target-by-Allogene Target basis and effective upon the filing of an IND for each individual Allogene Licensed Product developed under Section 4.1.2(a), Cellectis hereby grants to Allogene and its
Affiliates an exclusive (even as to Cellectis) license under the [***] Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such
Allogene Licensed Product in the Field in the Territory, with the right to sublicense as provided in Section 4.1.4. Notwithstanding the foregoing, Allogene hereby acknowledges and agrees that Cellectis shall have the right and obligation to
grant licenses and rights to a Third Party as set forth in Section 4.1.5(b) and Allogene’s license and other rights under the [***] Patent Rights shall be limited accordingly so long as any such agreement remains in effect with such Third
Party. For the sake of clarity, the license granted to Allogene by Cellectis herein does not give Allogene the right [***]. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 17 

 Confidential 
  

 (d)    Subject to the terms and conditions of this Agreement, on an
Other Product-by-Other Product basis and effective upon the filing of an IND for each individual Other Product developed under Section 4.1.2(b), Cellectis hereby
grants to Allogene and its Affiliates an exclusive (even as to Cellectis) license under the [***] Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit
and Commercialize such Other Product in the Other Field in the Other Territory, and Cellectis shall further have the obligation to grant the licenses and rights set forth in this Section 4.1.2(d) to subcontractors as directed by Allogene
pursuant to Section 4.1.5(b) herein. For the sake of clarity, the license granted to Allogene by Cellectis herein does not give Allogene the right [***]. 

(e)    Pursuant to Section 4.1.2(e) of the Research Collaboration and License Agreement, Allogene consented to the
license granted by Cellectis to Servier pursuant to the Servier Agreement. Further, the Parties acknowledged and agreed and hereby acknowledge and agree that any rights or licenses that have been granted to Servier at Allogene’s request
(including any expansions of such rights or licenses, pursuant to the Research Collaboration and License Agreement, that Allogene directs Cellectis in writing to grant to Servier), or that may hereafter be granted by Cellectis to Servier, a
subcontractor as directed by Servier, or a Third Party at the request of Allogene, are rights or licenses that were provided to Allogene pursuant to the Research Collaboration and License Agreement or this Agreement, and therefore Cellectis has
already received (or, in the future and in accordance with the terms of this Agreement, will have the right to receive) compensation that Cellectis and Allogene have determined is fair and equitable and that Cellectis shall therefore not have the
right to any additional payments or compensation from Servier, Allogene or any other person or entity in connection with the foregoing. Without limiting the foregoing, the Parties also agreed and acknowledged that all consideration paid or to be
paid, whether one-time payments, milestone payments, royalty payments or otherwise, to Cellectis under the Servier Agreement, the Research Collaboration and License Agreement, or this Agreement shall not be
reduced or otherwise modified or amended because of the license granted to Servier or other parties as contemplated thereby. 

4.1.3.    License to Cellectis Improvements. Subject to the terms and conditions of this Agreement, Cellectis hereby
grants to Allogene and its Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Cellectis Improvements that were solely or jointly invented by the
employees, agents or independent contractors of Allogene or its Affiliates to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and
processes. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 18 

 Confidential 
  

 4.1.4.    Right to Sublicense. Allogene will have the right to
grant sublicenses to its Affiliates and Third Parties of any and all licenses granted to Allogene under this Agreement by Cellectis, provided that (a) Allogene will be jointly and severally responsible with its Sublicensees to Cellectis for
failure by its Sublicensees to comply with the terms and conditions of this Agreement; (b) each sublicense will include obligations on the Sublicensee that are consistent with the terms of this Agreement; and (c) Allogene will remain
responsible for the payment to Cellectis of all Milestone Payments and royalties payable with respect to the activities and Net Sales of any Sublicensee. 

4.1.5.    Direct License  

(a)    Direct license to Affiliates. Allogene may at any time request and authorize Cellectis to grant licenses
directly to Affiliates of Allogene by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, Cellectis will enter into and sign a separate direct license agreement with such
designated Affiliate of Allogene. All such direct license agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and regulations in the country in which the direct
license will be exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this Agreement to the terms of this Agreement as set forth on the
Effective Date. In countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements will not become binding between the parties thereto until such approval or
registration is granted, which approval or registration will be obtained by Allogene. All costs of making such direct license agreement(s), including Cellectis’ reasonable attorneys’ fees, under this Section 4.1.5 will be borne by
Allogene. Cellectis may provide a copy of any such license or similar agreements (and this Agreement) to any direct or indirect licensors to the extent required to comply with the terms of any license agreement to which Cellectis is a party from
time to time. 
 (b)    Direct License to Third Parties. Allogene may at any time request and authorize Cellectis
to grant the rights and licenses set forth in Sections 4.1.2(a), 4.1.2(b), 4.1.2(c) and 4.1.2(d) of this Agreement directly to third parties by giving written notice designating to which Third Party such direct right or license is to be
granted. Upon receipt of any such notice, Cellectis will enter into and sign a separate direct license or similar agreement with such designated Third Party, which, to the extent involving [***] Patent Rights licensed to Cellectis by Life
Technologies Corporation, must include a license in respect of all of the [***] Patent Rights. All such 

  
 19 

 Confidential 
  

 
direct license or similar agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and regulations in the
country in which the direct license or right will be exercised. Cellectis may provide a copy of any such license or similar agreements to any of its direct or indirect licensors to the extent required to comply with the terms of any license
agreement to which Cellectis is a party from time to time. The parties further agree and acknowledge that no additional consideration would be due to Cellectis from Allogene or such Third Party in respect of the grant of any such license or similar
right, and the grant of any such license or similar right shall limit Allogene’s license and other rights accordingly so long as any such agreement remains in effect with such Third Party. The parties acknowledge and agree that any rights or
licenses that may hereafter be granted by Cellectis at the request of Allogene as contemplated by the immediately preceding sentence are rights or licenses that were previously provided to Allogene pursuant to this Agreement in accordance with the
broad collaboration and development activities contemplated by such agreement, and therefore Cellectis has already received (or, in the future and in accordance with the terms of this Agreement, will have the right to receive) compensation that
Cellectis and Allogene have determined is fair and equitable and that Cellectis shall therefore not have the right to any additional payments or compensation from Allogene or any other person or entity in connection with the foregoing. The parties
further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license or similar agreements and this Agreement to the terms of this Agreement. In countries where the validity of such direct
license or similar agreements requires prior governmental approval or registration, such direct license or similar agreements will not become binding between the parties thereto until such approval or registration is granted, which approval or
registration will be obtained by Allogene or the Third Party, as applicable.  
 4.1.6.    Right of
Reference. Cellectis hereby grants to Allogene a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b), to any data Controlled by Cellectis or its Affiliates (a) that relates to the Licensed Cellectis
Intellectual Property, the Agreement CAR-Ts, the Allogene Licensed Products or preclinical studies with respect to the Allogene Licensed Products and (b) that Allogene reasonably believes may be necessary
or useful to the Development, Manufacturing or Commercialization of any Agreement CAR-T or any Allogene Licensed Product pursuant to this Agreement, and Cellectis will provide a signed statement to the
foregoing effect, if so requested by Allogene in accordance with 21 C.F.R. § 314.50(g)(3). 

4.1.7.    Technology Transfer Assistance to Allogene. Cellectis will provide reasonable assistance, at no additional
cost to Allogene, to affect the timely and 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 

  
 20 

 Confidential 
  

 
orderly transfer to Allogene of the Know-How included in the Licensed Cellectis Intellectual Property necessary for the Development, Manufacturing and
Commercialization of Allogene Licensed Products pursuant to the License. 
 4.2.    Grants to Cellectis. 

4.2.1.    Non-Exclusive License. Subject to the terms and conditions of this
Agreement, Allogene hereby grants to Cellectis and its Affiliates a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under the Licensed Allogene Intellectual Property Controlled by
Allogene solely to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Cellectis Products Targeting Cellectis Program Targets. Cellectis will have the
right to grant sublicenses of the foregoing license to Third Party collaborators only if Cellectis has entered into a written agreement with such Third Party collaborator (a) obtaining a covenant not to sue or (b) granting Allogene a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under improvements to the Cellectis Technology developed in the framework of the collaboration between Cellectis and such Third Party that
are Controlled by such Third Party. 
 4.2.2.    License to Allogene Improvements. Subject to the terms and
conditions of this Agreement, Allogene hereby grants to Cellectis and its Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Allogene Improvements
that were solely or jointly invented by the employees, agents or independent contractors of Cellectis or its Affiliates to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise
exploit and Commercialize any products and processes. 
 4.2.3.    Technology Transfer Assistance to Cellectis.
Allogene will provide reasonable assistance, at no additional cost to Cellectis, to affect the timely and orderly transfer to Cellectis of the Know-How included in the Allogene Technology, Allogene
Improvements, Developed IP solely owned by Allogene, and CAR-T Developed IP (if applicable) necessary for the Development, Manufacturing and Commercialization of Cellectis Products Targeting Cellectis Programs
Targets pursuant to the License under Sections 4.2.1 and 4.2.2 above. 
 4.3.    Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information. Without limiting any other license granted to either Party under this Agreement and
subject to the terms of Article7: 
 4.3.1.    Cellectis hereby grants to Allogene and its Affiliates a non-exclusive, irrevocable, perpetual, non-transferable, royalty-free, fully paid-up, worldwide license to use any and all Cellectis Know-How included in the Licensed Cellectis Intellectual Property and Cellectis Confidential Information disclosed to Allogene (or Pfizer prior to the Assignment) during the term of the Research Collaboration and
License Agreement or during the Term of this Agreement solely for internal research purposes. 

  
 21 

 Confidential 
  

 4.3.2.    Allogene hereby grants to Cellectis and its Affiliates a non-exclusive, irrevocable, perpetual, non-transferable, royalty-free, fully paid-up, worldwide license to use any and all Allogene Know-How and Allogene Confidential Information (other than any information regarding the identity of or Allogene’s reasons for selecting any Allogene Target or Additional Allogene Target, which will only be
disclosed by Cellectis to its Representatives as necessary to comply with the terms of this Agreement) disclosed to Cellectis during the term of the Research Collaboration and License Agreement or during the Term of this Agreement solely for
internal research purposes. 
 4.3.3.    Notwithstanding the foregoing, neither Allogene nor Cellectis will have any
right under this Section 4.3 to make or use any physical material supplied by the other Party for use in the Research Program other than for use in the Research Program. 

4.4.    Retained Rights. For the avoidance of doubt, except as expressly provided in regard to the licenses
contained in this Article 4 or in the provisions of Section 6.1.1, each Party will retain ownership of all of its Allogene Technology or Cellectis Technology, as applicable. 

4.5.    Other Allogene Programs. Cellectis understands and acknowledges that Allogene may have present or future
initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving similar products, programs, technologies or processes that are similar to or that may compete with a product, program, technology or
process covered by this Agreement. Cellectis acknowledges and agrees that nothing in this Agreement will be construed as a representation, warranty, covenant or inference that Allogene will not itself Develop, Manufacture or Commercialize or
enter into business relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize products, programs, technologies or processes that are similar to or that may compete with any product, program,
technology or process covered by this Agreement. Notwithstanding the foregoing, if Allogene or its Affiliates, other than pursuant to this Agreement, themselves Develop, Manufacture or Commercialize or enter into business relationships with one or
more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize T-cells expressing a chimeric antigen receptor construct other than a CAR-T, with
respect to a particular Allogene Target in the Field, then any exclusive licenses granted to Allogene under this Agreement with respect to an Allogene Licensed Product Targeting such Allogene Target will be automatically converted into non-exclusive
licenses, and Cellectis’ exclusivity obligation under Section 2.1 will not apply with respect to such Allogene Target. 

4.6.    No Implied Rights. Except as expressly provided in this Agreement, neither Party will be deemed, by
estoppel, implication or otherwise, to have granted the other Party any license or other right with respect to any intellectual property of such Party. 

  
 22 

 Confidential 
  

 5.    PAYMENTS TO CELLECTIS. 

5.1.     Milestones 

5.1.1.    Development Milestones. Within [***] of receipt of Cellectis’ invoice following the first occurrence
of each event described below (each, a “Development Milestone”) for each Allogene Licensed Product for each Allogene Target, Allogene will pay to Cellectis the amount set forth below (each, a “Development Milestone
Payment”) to be payable only once with respect to each Allogene Licensed Product Targeting an Allogene Target. For the avoidance of doubt, if any Development Milestone Payment is paid for an Agreement
CAR-T or Allogene Licensed Product Targeting an Allogene Target and the Development or Commercialization of such Agreement CAR-T or Allogene Licensed Product is
terminated and such Agreement CAR-T or Allogene Licensed Product is replaced with another Agreement CAR-T or Allogene Licensed Product Targeting the same Allogene
Target, such Development Milestone Payment will not be owed by Allogene if such Agreement CAR-T or Allogene Licensed Product later achieves the same Development Milestone. 

 

			
	 Development Milestone
	  	 Development Milestone Payments

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 If any Development Milestone occurs before a previous Development Milestone occurs, then any Development
Milestone that has not yet been paid for achievement of any previous Development Milestone shall become due upon the achievement of the subsequent Development Milestone and payable together with the payment due upon achievement of such subsequent
Development Milestone. For clarity, the achievement of a Development Milestone related to [***] will not result in the payment of any other Development Milestone related to [***]. 

5.1.2.    Sales Milestones. Allogene will pay to Cellectis the following
one-time payments (each, a “Sales Milestone Payment”) within [***] of the last day of the Calendar Year when aggregate Annual Net Sales of an Allogene Licensed Product in a Calendar Year first
reach the respective threshold (a “Sales Threshold”) indicated below (each, a “Sales Milestone”); provided that such Sales Threshold with respect to an Allogene Licensed Product must be reached within [***]
following the First Commercial Sale of such Allogene Licensed Product in the Territory. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 23 

 Confidential 
  

			
	 Total Annual Net Sales
	  	 Sales Milestone Payments

	[***]	  	[***]
	[***]	  	[***]

 5.2.    Royalties. With respect to each Allogene Licensed Product and subject to the
provisions of Section 5.2.2, Allogene will pay Cellectis royalties in the amount of the applicable rates (“Marginal Royalty Rates”) set forth below of Annual Net Sales of any Allogene Licensed Product Targeting such Allogene
Target during the Royalty Term: 
  

			
	 Annual Net Sales
	  	 Marginal Royalty Rates

(% of the Annual Net Sales)

	[***]	  	[***]
	[***]	  	[***]

 5.2.1.    Marginal Royalty Rate Application. Each Marginal Royalty Rate set forth in
the table above will apply only to that portion of the Annual Net Sales of a given Allogene Licensed Product in the Territory during a given Calendar Year that falls within the indicated range. 

5.2.2.    Royalty Adjustments. The following adjustments will be made, on an Allogene Licensed Product-by-Allogene Licensed Product and country-by-country basis, to the royalties payable
pursuant to this Section 5.2: 
 (a)    Generic Competition. Royalties payable following establishment of
Generic Competition with respect to the sale by a Third Party of a product that is a Biosimilar Biologic Product to such Allogene Licensed Product in such country will be payable at [***] of the otherwise applicable rate prior to application of this
Section 5.2.2(a). “Generic Competition” means, with respect to a given Calendar Year with respect to an Allogene Licensed Product in any country, that during such Calendar Year, one (1) or more Third Parties have received
Regulatory Approval to sell in such country a Biosimilar Biologic Product, such Biosimilar Biologic Product(s) will be commercially available in such country and such Biosimilar Biologic Product(s) will have, in the aggregate. A product will be a
“Biosimilar Biologic Product” with respect to an Allogene Licensed Product if such product (1) has been licensed as a biosimilar or interchangeable product by FDA pursuant to Section 351(k) of the Public Health Service Act
(42 U.S.C. 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation, (2) has been licensed as a similar biological medicinal product by EMA pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or
superseding law, statute or regulation, or (3) has otherwise achieved analogous Regulatory Approval from another applicable Regulatory Authority. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 24 

 Confidential 
  

 (b)    Third Party Patents. If, after June 17, 2014,
it was or is Necessary or Useful for Allogene (or Pfizer, to the extent identified by Pfizer prior to the Assignment) to license one or more Patent Rights from one or more Third Parties in order to Develop, Manufacture, Commercialize or use any
Allogene Licensed Product, whether directly or through any Allogene Affiliate or Sublicensee, then Allogene may, in its sole discretion, negotiate and obtain a license under such Patent Right(s) (each such Third Party license, or any such Third
Party license entered into as of the Effective Date by Allogene or by Pfizer and assigned to Allogene, referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to Cellectis under this Agreement with
respect to Net Sales of any Allogene Licensed Product by Allogene, its Affiliates or Sublicensees will be reduced by [***] of the amounts payable to Third Parties pursuant to any Additional Third Party Licenses, such reduction to continue until all
such amounts have been expended, provided that in no event will the total royalty payable to Cellectis for any Allogene Licensed Product be less than [***] of the royalty amounts otherwise payable for such Allogene Licensed Product and in no event
will the royalty payable to Cellectis for any Allogene Licensed Product be reduced below [***] (in each case, other than in the case of Cellectis’ breach of any representation, warranty or covenant hereunder). For purposes of this
Section 5.2.2(b), (i) “Necessary” means that, without a license to use the Third Party’s Patent Right, the Development, Manufacture, Commercialization or use of any Allogene Licensed Product in the form such Allogene
Licensed Product exists at the time that the Additional Third Party License is executed would, in Allogene’s opinion, infringe such Third Party’s Patent Right and (ii) “Useful” means that Allogene has determined in its
discretion that use of such Third Party’s Patent Right would enhance the commercial potential of such Allogene Licensed Product. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.2.2(b) will not apply with
respect to royalties payable by Allogene to any Third Party under any agreement in existence as of June 17, 2014. Neither Party will intentionally negotiate with a Third Party an exclusive license that excludes sublicense rights to the other
Party, in the event such Third Party rights are necessary, as determined by the negotiating Party, to Develop and Commercialize Allogene Licensed Products and Cellectis Products in connection with this Agreement in the Field. 

(c)    Cellectis Third Party Agreements. Cellectis will be solely responsible for all obligations, including
royalty obligations, that are due and owing or may become due and owing with respect to any Cellectis Third Party Agreements that are in effect as of the Effective Date or that Cellectis or any of its Affiliates enters into during the Term of this
Agreement. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 25 

 Confidential 
  

 5.2.3.    Fully Paid-Up,
Royalty Free License. After expiration of the Royalty Term for any Allogene Licensed Product in a country in the Territory, no further royalties will be payable in respect of sales of such Allogene Licensed Product in such country and thereafter
the License with respect to such Allogene Licensed Product in such country will be a fully paid-up, perpetual, exclusive, irrevocable, royalty-free license. 

5.3.    Diagnostic and Prognostic Products. In no event will any milestone, net sales or royalty payments become due
or owing pursuant to Section 5.1 or 5.2 above with respect to any Allogene Licensed Product Developed or Commercialized for diagnostic or prognostic purposes. 

5.4.    Reports and Payments.  

5.4.1.    Cumulative Royalties. The obligation to pay royalties under Section 5.2 will be imposed only once
with respect to a single unit of an Allogene Licensed Product regardless of how many Valid Claims in Patent Rights included within the Licensed Cellectis Intellectual Property would, but for this Agreement, be infringed by the use or sale of such
Allogene Licensed Product in the country in which such Allogene Licensed Product is used or sold. 
 5.4.2.    Royalty
Statements and Payments. Within [***] after the end of each Calendar Quarter, Allogene will deliver to Cellectis a report setting forth for such Calendar Quarter the following information, on an Allogene Licensed
Product-by-Allogene Licensed Product basis: (a) the Net Sales of each Allogene Licensed Product, (b) the basis for any adjustments to the royalty payable for the sale of each Allogene Licensed
Product and (c) the royalty due hereunder for the sale of each Allogene Licensed Product. No such reports will be due for any Allogene Licensed Product before the First Commercial Sale of such Allogene Licensed Product in the Territory. The
total royalty due for the sale of Allogene Licensed Products during such Calendar Quarter will be remitted at the time such report is delivered to Cellectis. 

5.4.3.    Taxes and Withholding. It is understood and agreed between the Parties that any payments made under this
Agreement are exclusive of any value added or similar tax (“VAT”), which will be added thereon as applicable. Where VAT is properly added to a payment made under this Agreement, the party making the payment will pay the amount of
VAT only on receipt of a valid tax invoice issued in accordance with the laws and regulations of the country in which the VAT is chargeable. In addition, in the event any of the payments made by Allogene pursuant to this Agreement become subject to
withholding taxes under the Laws of any jurisdiction, Allogene will deduct and withhold the amount of such taxes for 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 26 

 Confidential 
  

 
the account of Cellectis, to the extent required by Law, such amounts payable to Cellectis will be reduced by the amount of taxes deducted and withheld, and Allogene will pay the amounts of such
taxes to the proper Governmental Authority in a timely manner and promptly transmit to Cellectis an official tax certificate or other evidence of such tax obligations together with proof of payment from the relevant Governmental Authority of all
amounts deducted and withheld sufficient to enable Cellectis to claim such payment of taxes. Any such withholding taxes required under applicable Law to be paid or withheld will be an expense of, and borne solely by, Cellectis. Allogene will provide
Cellectis with reasonable assistance to enable Cellectis to recover such taxes as permitted by Law. 

5.4.4.    Currency. All amounts payable and calculations hereunder will be in United States dollars. As applicable,
Net Sales and any royalty deductions will be converted into United States dollars in accordance with Allogene’s customary and usual conversion procedures, consistently applied. 

5.4.5.    Method of Payment. Except as permitted pursuant to Section 5.4.4, each payment hereunder will be made
by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Allogene’s election, to such bank account as the Cellectis
will designate in writing to Allogene at least forty-five (45) days before the payment is due. 

5.4.6.    Additional Provisions Relating to Payments. Cellectis acknowledges and agrees that nothing in this
Agreement (including any schedules and exhibits hereto) will be construed as representing an estimate or projection of either (a) the number of Allogene Licensed Products that will or may be successfully Developed or Commercialized or
(b) anticipated sales or the actual value of any Allogene Licensed Product. ALLOGENE MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF
COMMERCIALIZED, THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL OF SUCH PRODUCT(S), PROVIDED THAT THE FOREGOING WILL NOT LIMIT ALLOGENE’S OBLIGATIONS UNDER THIS AGREEMENT. 

5.5.    Maintenance of Records; Audits. 

5.5.1.    Record Keeping. Allogene will keep, and cause its Affiliates and Sublicensees to keep, accurate books of
account and records in connection with the sale of Allogene Licensed Products, in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. Allogene will maintain, and cause its
Affiliates and Sublicensees to maintain, such records for a period of at least [***] after the end of the Calendar Year in which they were generated. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 27 

 Confidential 
  

 5.5.2.    Audits. Upon thirty (30) days prior written notice
from Cellectis, Allogene will permit an independent certified public accounting firm of internationally recognized standing selected by Cellectis and reasonably acceptable to Allogene to examine, at Cellectis’ sole expense, the relevant books
and records of Allogene during the period covered by such examination, as may be reasonably necessary to verify the accuracy of the reports submitted by Allogene in accordance with Section 5.4 and the payment of royalties hereunder. An
examination by Cellectis under this Section 5.5.2 will occur not more than [***] and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] before the date of the request. The accounting firm
will be provided access to such books and records at Allogene’s or its Affiliates’ facilities where such books and records are kept and such examination will be conducted during Allogene’s normal business hours. Allogene may require
the accounting firm to sign a reasonable and customary non-disclosure agreement before providing the accounting firm access to Allogene’s facilities or records. Upon completion of the audit, the
accounting firm will provide both Allogene and Cellectis a written report disclosing whether the reports submitted by Allogene are correct or incorrect, whether the royalties paid are correct or incorrect and, in each case, the specific details
concerning any discrepancies. No other information will be provided to Cellectis. 

5.5.3.    Underpayments/Overpayments. If such accounting firm concludes that additional royalties were due to
Cellectis, Allogene will pay to Cellectis the additional royalties within thirty (30) days of the date Allogene receives such accountant’s written report so concluding. If such underpayment exceeds [***] of the royalties that were to be
paid to Cellectis, Allogene also will reimburse Cellectis for all reasonable charges of such accountants for conducting the audit. If such accounting firm concludes that Allogene overpaid royalties to Cellectis, Cellectis will repay such amount to
Allogene in full within thirty (30) days of the receipt of such accountant’s report, or, at Allogene’s option, Allogene will be entitled to offset all such overpayments against any outstanding or future amounts payable to Cellectis
hereunder until Allogene has received full credit for such overpayments. 
 5.5.4.    Confidentiality. All
financial information of Allogene which is subject to review under this Section 5.5 will be deemed to be Allogene’s Confidential Information subject to the provisions of Article 7 hereof, and Cellectis will not disclose such
Confidential Information to any Third Party or use such Confidential Information for any purpose other than verifying payments to be made by Allogene to Cellectis hereunder. 

5.5.5.    Costs. Cellectis shall pay the full cost of the audit unless the discrepancy is to the Cellectis’
detriment and is greater than [***] of all amounts due in such calendar year, in which cases Allogene shall pay the reasonable cost charged by such accountant for such inspection. 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 28 

 Confidential 
  

 5.6.    No Guarantee of Success. Allogene and Cellectis
acknowledge and agree that payments to Cellectis pursuant to Sections 5.1 and 5.2: (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if an Allogene Licensed Product is successfully Developed
or Commercialized, as applicable; (b) are solely intended to allocate amounts that may be achieved upon successful Development or Commercialization of an Allogene Licensed Product between Allogene (who will receive all Allogene Licensed Product
sales revenues) and Cellectis; (c) are not intended to be used and will not be used as a measure of damages if this Agreement is terminated for any reason, including pursuant to Allogene’s right to terminate at for convenience, before any
such success is achieved and such amounts become due; and (d) will only be triggered, and will only be relevant as provided, in accordance with the terms and conditions of such provisions. Allogene and Cellectis further acknowledge and agree
that nothing in this Agreement will be construed as representing any estimate or projection of (i) the successful Development or Commercialization of any Allogene Licensed Product under this Agreement, (ii) the number of Allogene Licensed
Products that will or may be successfully Developed or Commercialized under this Agreement, (iii) anticipated sales or the actual value of any Allogene Licensed Products that may be successfully Developed or Commercialized under this Agreement
or (iv) the damages, if any, that may be payable if this Agreement is terminated for any reason. Allogene makes no representation, warranty or covenant, either express or implied, that (A) it will successfully Develop, Manufacture,
Commercialize or continue to Develop, Manufacture or Commercialize any Allogene Licensed Product in any country, (B) if Commercialized, that any Allogene Licensed Product will achieve any particular sales level, whether in any individual
country or cumulatively throughout the Territory or (C) Allogene will devote, or cause to be devoted, any level of diligence or resources to Developing or Commercializing any Allogene Licensed Product in any country, or in the Territory in
general, other than is expressly required under Section 2.2. 
  

	6.	 INTELLECTUAL PROPERTY. 

6.1.    Inventions. 

6.1.1.    Ownership. All determinations of inventorship under this Agreement will be made in accordance with the
laws of the United States. 
 (a)    Allogene Improvements. Allogene will own all [***]. 

(b)    Cellectis Improvements. Cellectis will own all [***]. 

(c)    Developed IP. [***]. 

(d)    Allogene CAR-T Developed IP. [***]. 

(e)    Cellectis CAR-T Developed IP. [***]. 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 29 

 Confidential 
  

 (f)    Implementation. Each Party will assign, and does hereby
assign, to the other Party such Patent Rights, Know-How or other intellectual property rights as necessary to achieve ownership as provided in this Section 6.1.1. Each assigning Party will execute and
deliver all documents and instruments reasonably requested by the other Party to evidence or record such assignment or to file for, perfect or enforce the assigned rights. Each assigning Party will make its relevant employees, agents and independent
contractors (and their assignments and signatures on such documents and instruments) reasonably available to the other Party for assistance in accordance with this Section 6.1.1 at no charge. 

6.1.2.    Disclosure. Each Party will promptly (and in no event less than [***] before filing any initial Patent
Right disclosing such intellectual property) disclose to the other Party any Developed IP, Cellectis Improvement or Allogene Improvement, including all invention disclosures or other similar documents submitted to such Party by its, or its
Affiliates’, employees, agents or independent contractors describing such Developed IP, Cellectis Improvement or Allogene Improvement, and the proposed inventorship of any new Patent Rights intended to be filed. The other Party will promptly
raise any issue regarding inventorship. Any inventorship issue raised more than [***] after notice of the filing of an initial Patent Rights and the content thereof, or the subsequent filing of new patent claims in a Patent Right directed to
substantially different inventions, will not affect ownership of the Patent Right as determined in accordance with the initial inventorship determination. 

6.2.    Patent Rights. 

6.2.1.    Filing, Prosecution and Maintenance of Patent Rights. 

(a)    Cooperation. Without limiting any other rights and obligations of the Parties under this Agreement, the
Parties will cooperate with respect to the timing, scope and filing of patent applications and patent claims relating to any Cellectis Improvements, Allogene Improvements and Developed IP to preserve and enhance the patent protection for Agreement CAR-Ts, including the manufacture and use thereof. If the ownership rights in any Patent Rights included in Cellectis Improvements or Developed IP are substantially impeding or would substantially impede
Allogene’s prosecution of Allogene CAR-T Developed IP, or Cellectis’s prosecution of Cellectis CAR-T Developed IP, the Parties will negotiate in good faith an
amendment of the ownership of such Patent Rights included in Cellectis Improvements or Developed IP while preserving for each Party substantially the same rights, including all Milestone Payments and royalty payments, as are afforded in this
Agreement. 
 (b)    Allogene Patent Rights. Allogene, at its own expense, will have the sole right, but not the
obligation, to prepare, file, prosecute and maintain, 

  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 30 

 Confidential 
  

 
throughout the world, any Patent Rights that it solely owns, including Allogene Patent Rights and Patent Rights comprised in the Allogene Improvements and Allogene
CAR-T Developed IP. Allogene will keep Cellectis informed regarding the status of any Patent Right comprised in any such CAR-T Developed IP at Cellectis’ reasonable
request. To the extent Allogene wishes not to file, prosecute or maintain any such Patent Right, Allogene will provide Cellectis with thirty (30) days prior written notice to such effect, in which event Cellectis may elect to continue filing,
prosecution or maintenance of such Patent Right, and Allogene, upon Cellectis’ written request received within such thirty (30) day period, will execute such documents and perform such acts, at Cellectis’ expense, as may be reasonably
necessary to permit Cellectis to file, prosecute and maintain such Patent Right. Any such Patent Right that is prosecuted or maintained by Cellectis pursuant to this Section 6.2.1(b): (i) will continue to be owned by Allogene, and
(ii) subject to the Parties’ other rights and obligations under this Agreement, may be licensed by Allogene to one or more Third Parties. 

(c)    Cellectis Patent Rights. Cellectis, at its own expense, will have the sole right, but not the
obligation, to prepare, file, prosecute and maintain, throughout the world, any Patent Rights included in Licensed Intellectual Property that it solely owns or has in-licensed from Third Parties, including
Cellectis Patent Rights and Patent Rights comprised in the Cellectis Improvements. Cellectis will not disclose any Allogene Confidential Information in any Patent Rights that it files, or in connection with the prosecution of any such Patent Rights,
without Allogene’s prior written consent. Cellectis will notify Allogene promptly upon filing or otherwise obtaining rights in any Patent Right after the Effective Date that covers or may cover the Development, Manufacture, Commercialization or
use of any Allogene Licensed Product. In the absence of such prompt notification, any such Patent Rights will be excluded from the Valid Claim definition. Cellectis will keep Allogene informed regarding each Patent Right included in the Licensed
Intellectual Property that Cellectis or any Third Party licensor is prosecuting and will consider in good faith any recommendations made by Allogene in regard to the filing, prosecution or maintenance of any such Patent Right. To the extent
Cellectis wishes not to file, prosecute or maintain any such Patent Right (other than any such Patent Right owned or co-owned by a Third Party licensor), Cellectis will provide Allogene with thirty
(30) days prior written notice to such effect, in which event Allogene may elect to continue filing, prosecution or maintenance of such Patent Right, and Cellectis, upon Allogene’s written request received within such thirty (30) day
period, will execute such documents and perform such acts, at Allogene’s expense, as may be reasonably necessary to permit Allogene to file, prosecute and maintain, at its own discretion, such Patent Right. Any such Patent Rights that are
prosecuted or maintained by Allogene pursuant to this Section 6.2.1(c) will continue to be owned by Cellectis, and will be 

  
 31 

 Confidential 
  

 
excluded from the Valid Claim definition; and, in addition to the exclusive licenses granted to Allogene under Section 4.1, Cellectis will and does hereby grant to Allogene (subject to any
existing Third Party rights) a non-exclusive, sublicensable, perpetual, irrevocable, royalty-free, fully paid-up, worldwide license to practice and exploit such Patent
Rights for any and all purposes. Cellectis will not decline to pay for or participate in the filing, prosecution or maintenance of any Patent Right under any Cellectis Third Party Agreement that is included in the Licensed Intellectual Property
without Allogene’s prior written consent. 
 (d)    Joint Patent Rights. In the event the Parties conceive
or generate any Joint Developed IP, other than any Joint Developed IP that constitutes Allogene CAR-T Developed IP, or Cellectis CAR-T Developed IP, the Parties will
promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Patent Right covering or claiming any such Joint Developed IP (a “Joint Patent Right”) Allogene
will have the first right to file on and control prosecution of any Patent Right covering or claiming any Joint Developed IP used in the development, manufacture, composition or use of any CAR-T Targeting such
Allogene Target in accordance with Section 6.2.1(b). For avoidance of doubt, “prosecution” as used in this Section 6.2.1 includes oppositions, nullity or revocation actions, post-grant reviews and other patent office proceedings
involving the referenced Patent Rights. 
 (e)    Liability. To the extent that a Party is obtaining, prosecuting
or maintaining a Patent Right included in the Licensed Intellectual Property or Developed IP (including CAR-T Developed IP) or otherwise exercising its rights under this Section 6.2.1, such Party, and its
Affiliates, employees, agents or representatives, will not be liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or its Affiliates, employees, agents or representatives, in connection with
such activities undertaken in good faith. 
 (f)    Extensions. The decision to file for a patent term extension
and particulars thereof (including which patent(s) to extend) will be made with the goal of obtaining the optimal patent term and scope of protection for Allogene Licensed Products. Allogene will have the sole right but not the obligation to apply
for and obtain any patent term extension or related extension of rights, including supplementary protection certificates and similar rights, for any patent relating to an Allogene Licensed Product (including the choice of which patent(s) to extend),
provided that it will consult with Cellectis before applying for or obtaining any such extensions or rights for any patents included in the Licensed Cellectis Intellectual Property. The Parties will provide reasonable assistance to each other in
connection with obtaining any such extensions for any patent included in the Licensed Cellectis Intellectual Property. To the extent reasonably and 

  
 32 

 Confidential 
  

 
legally required in order to obtain any such extension in a particular country, each Party will make available to the other a copy of the necessary documentation to enable such other Party to use
the same for the purpose of obtaining the extension in such country. 
 (g)    Joint Research Agreement. This
Agreement will be understood to be a joint research agreement under 35 U.S.C. § 103(c)(3) entered into for the purpose of researching, identifying and Developing Agreement CAR-Ts and Allogene Licensed
Products. 
 (h)    Recording. If a Party deems it necessary or desirable to register or record this Agreement or
evidence of this Agreement with any patent office or other appropriate government authorities in one or more jurisdictions in the Territory, then the Parties will agree on a proposed evidence of such recording and the Parties will comply with the
terms of Section 7.2.3 in respect of such filing. Each Party will execute and deliver to the other Party any documents necessary or desirable to complete such registration or recordation in accordance with the terms of Section 7.2.3. 

6.2.2.    Enforcement of Patent Rights. 

(a)    Notice. If either Allogene or Cellectis becomes aware of any infringement that may affect competition of
either Party within the Field, anywhere in the world, of any issued Patent Right within the Licensed Intellectual Property or Developed IP, such Party will promptly notify the other Party in writing to that effect. 

(b)    Infringement of Certain Patent Rights.  

(i)    Subject to the terms and conditions of any applicable Cellectis Third Party Agreements, if any infringement of a
Patent Right included in the Licensed Intellectual Property by a Third Party arises from the Development, Manufacture or Commercialization of a product that does, or may, compete with an Allogene Licensed Product Targeting such Allogene Target,
Allogene will have the first right, but not the obligation, to take action to obtain a discontinuance of infringement or bring suit against a Third Party infringer of such Patent Right within six (6) months from the date of notice and to join
Cellectis as a party plaintiff in each of the following circumstances: (x) where the Allogene Licensed Product with which the Third Party’s infringement will compete has been [***] or is the subject of [***] and no Cellectis Product or CAR-T product of another Cellectis licensee has begun or completed [***], or (y) where such Patent Right is directed exclusively to an Allogene 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 

  
 33 

 Confidential 
  

 
Target or an Allogene Licensed Product Targeting such Allogene Target or an Allogene Licensed Product Targeting such Allogene Target; in all other circumstances, Allogene may, with prior written
consent of Cellectis (not to be unreasonably withheld), have the right to take action against such Third Party infringer. 

(ii)    Allogene will bear all the expenses of any suit brought by it claiming infringement of any such Patent Right.
Cellectis will cooperate with Allogene in any such suit and will have the right to consult with Allogene and to participate in and be represented by independent counsel in such litigation at its own expense. Allogene will incur no liability to
Cellectis as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Patent Right invalid or unenforceable, and Allogene will not, without Cellectis’ prior written consent, enter
into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Cellectis or admits the invalidity or unenforceability of any such Patent Right. 

(iii)    If Allogene has not obtained a discontinuance of infringement by, or filed suit against, any such Third Party
infringer within the six (6) month period set forth in subsection (i) above, then Cellectis will have the right, but not the obligation, to bring suit against such Third Party infringer, at Cellectis’ sole expense; provided, however,
that Cellectis will only have the foregoing right if Allogene would not be required (by Applicable Law or otherwise) to join such suit as a party and such suit would not involve a Patent Right covering a then-existing Agreement CAR-T or Allogene Licensed Product. Allogene will have no obligation to cooperate with Cellectis in any such litigation, provided that Allogene may, at its sole discretion, elect to consult with Cellectis and to
participate in and be represented by independent counsel in such litigation at its own expense. Cellectis will incur no liability to Allogene as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision
holding any such Cellectis Patent Right or Joint Patent Right invalid or unenforceable; and Cellectis will not, without Allogene’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or
imparts any other liability to Allogene or admits the invalidity or unenforceability of any such Patent Right. 

(iv)    The enforcing Party will keep the other Party reasonably informed of all material developments in connection with
any such suit. Subject to the terms and conditions of any applicable Cellectis Third Party Agreements, any recoveries obtained by either Party as a result of any proceeding against such a Third Party infringer will be allocated as follows: 

  
 34 

 Confidential 
  

 (A)    Such recovery will first be used to reimburse each Party for all out-of-pocket litigation costs in connection with such litigation paid by that Party; and 

(B)    With respect to any remaining portion of such recovery, if Allogene was the enforcing Party, Cellectis will receive
an amount equal to the royalty that would be payable, pursuant to Section 5.2, on an amount of Net Sales of the relevant Allogene Licensed Product(s) in the country(ies) where such infringement occurred equal to such remaining portion of such
recovery, and Allogene will receive any remaining portion of such recovery; or 
 (C)    With respect to any remaining
portion of such recovery, if Cellectis was the enforcing Party, Cellectis will receive any remaining portion of such recovery, except to the extent such recovery was calculated based on lost sales of Allogene, in which case the allocation of such
remaining portion will be made as provided in Section 6.2.2(b)(iv)(B). 
 (c)    Other Infringement of Joint
Patent Rights. With respect to any notice of a Third Party infringer of any Joint Patent Right other than in the case of a Joint Patent Right subject to Section 6.2.2(b), the Parties will meet as soon as reasonably practicable to discuss
such infringement and determine an appropriate course of action and the Parties’ respective rights and responsibilities with respect to any enforcement thereof. 

6.2.3.        Biosimilar Notices.  

(a)    General Strategy. Upon Allogene’s request any time after completion of the first Phase II Clinical
Trial for any Allogene Licensed Product, Cellectis will use reasonable efforts to assist and cooperate with Allogene in establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and
preparing submissions responsive to any Biosimilar Notices received by Allogene; provided that Allogene will make the final decisions with respect to such strategy and any such responses. 

(b)    Biosimilar Notices. Allogene will comply with the applicable provisions of 42 U.S.C. § 262(l) (or any
amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products in the United States, or any similar statutory or regulatory requirement in any
non-U.S. country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received by Allogene from any Third Party regarding any Allogene Licensed Product that is being
Commercialized in the applicable jurisdiction, and the exchange of information between any Third Party and 

  
 35 

 Confidential 
  

 
Allogene pursuant to such requirements; provided that, prior to any submission of information by Allogene to a Third Party, Cellectis will have the right to review the patent information included
in such proposed submission, solely with respect to Patent Rights Controlled by Cellectis, and to make suggestions as to any changes to such patent information that Cellectis reasonably believes to be necessary; provided further that Allogene will
determine the final content of any such submission. In the case of an Allogene Licensed Product approved in the United States under the PHS Act (or, in the case of a country in the Territory other than the United States, any similar law), to the
extent permitted by Applicable Law, Allogene, as the sponsor of the application for the Allogene Licensed Product, will be the “reference product sponsor” under the PHS Act. Allogene will give written notice to Cellectis of receipt of a
Biosimilar Notice received by Allogene with respect to an Allogene Licensed Product, and Allogene will consult with Cellectis with respect to the selection of the Patent Rights to be submitted pursuant to 42 U.S.C. § 262(l) (or any similar
law in any country of the Territory outside the United States); provided that Allogene will have final say on such selection of Patent Rights. Cellectis agrees to be bound by the confidentiality provisions of 42 U.S.C. § 262(l)(1)(B)(iii). In
order to establish standing in connection with any action brought by Allogene under this Section 6.2.3, Cellectis, upon Allogene’s request, will reasonably cooperate with Allogene in any such action, including timely commencing or joining
in any action brought by Allogene under this Section 6.2.3 solely to the extent any Patent Rights Controlled by Cellectis are involved in any such action, and the Parties rights and responsibilities regarding any action will be determined in
accordance with Section 6.2.2(b). 
 6.3.    Interference, Opposition, Revocation and Declaratory Judgment
Actions. If the Parties mutually determine that, based upon the review of a Third Party’s patent or patent application or other intellectual property rights, it may be desirable in connection with any Agreement CAR-T or Allogene Licensed Product to provoke or institute an interference, opposition, revocation, post-grant review or other patent office proceedings or declaratory judgment action with respect thereto, then the
Parties will consult with one another and will [***] in connection with such an action. Unless otherwise mutually determined by the Parties, Allogene will control such action and will select counsel for such action. The rights and obligations of the
Parties under Section 6.4 are expressly subject to this Section 6.3. 
 6.4.    Infringement of Third Party
Patent Rights. If the Development, Manufacture or Commercialization of any Allogene Licensed Product is alleged by a Third Party to infringe a Third Party’s patent or other intellectual property rights, the Party becoming aware of
such allegation will promptly notify the other Party. The Party that is alleged to infringe the Third Party’s patent or intellectual property rights will have the right to take such action as it deems appropriate in response to such allegation,
and will be solely responsible for all damages, costs and expenses in connection therewith, subject to Section 10.1. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 36 

 Confidential 
  

	7.	 CONFIDENTIALITY 

7.1.    Confidentiality. Except to the extent expressly authorized by this Agreement, the Parties agree that, during
the Term and [***], each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will: (a) keep the Disclosing Party’s Confidential
Information confidential; (b) not disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose,
provided, however, that a Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information (i) was already known by the Receiving Party (other than under an obligation of
confidentiality to the Disclosing Party) at the time of disclosure by the Disclosing Party; (ii) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;
(iii) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement;
(iv) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving Party; or (v) was independently
discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information of the Disclosing Party. 

7.2.    Authorized Disclosure. 

7.2.1.    Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 7.1, the
Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s, its Affiliates’ and its Sublicensees’ officers, directors, employees, consultants, contractors, licensors and agents
(collectively, “Representatives”) who (a) have a need to know such Confidential Information in connection with the performance of the Receiving Party’s obligations or the exercise of the Receiving Party’s rights under
this Agreement and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as
restrictive as those set forth in this Article 7. 
 7.2.2.    Disclosure to Third Parties. 

(a)    Notwithstanding the foregoing provisions of Section 7.1, the Parties may disclose Confidential Information
belonging to the other Party: 
 (i)    to Governmental Authorities (A) to the extent reasonably necessary to
obtain or maintain INDs or Regulatory Approvals for any Agreement CAR-T or Allogene Licensed Product Targeting 

  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 37 

 Confidential 
  

 
such Allogene Target, or any Cellectis Target or Cellectis Product Targeting such Cellectis Target, within the Territory, and (B) in order to respond to inquiries, requests, investigations,
orders or subpoenas relating to this Agreement; 
 (ii)    to outside consultants, contractors, advisory boards, managed
care organizations, and non-clinical and clinical investigators, in each case to the extent reasonably necessary for the performance of this Agreement and under reasonable obligations of confidentiality; 

(iii)    to the extent reasonably necessary, in connection with filing or prosecuting Patent Rights or Trademark rights as
permitted by this Agreement; 
 (iv)    to the extent reasonably necessary, in connection with prosecuting or defending
litigation as permitted by this Agreement; 
 (v)    subject to Section 7.3.2, in connection with or included in
scientific presentations and publications relating to Agreement CAR-Ts or Allogene Licensed Products, including abstracts, posters, journal articles and the like, and posting results of and other information
about clinical trials to clincialtrials.gov or PhRMA websites; and 
 (vi)    to the extent necessary in order to
enforce its rights under this Agreement and as permitted in the Agreement. 
 (b)    In the event a Party deems it
reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to Section 7.2.2(a)(i)(B), the Disclosing Party will to the extent possible give reasonable advance written notice of such disclosure to the other
Party and take all reasonable measures to ensure confidential treatment of such information. 
 7.2.3.    SEC Filings
and Other Disclosures. Notwithstanding any provision of this Agreement to the contrary, either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with
applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory. Notwithstanding the foregoing, before disclosing this
Agreement or any of the terms hereof pursuant to this Section 7.2.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure. Further, if a Party discloses this Agreement or any of
the terms hereof in accordance with this Section 7.2.3, such Party will, at its own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party.

  
 38 

 Confidential 
  

 7.3.      Public Announcements; Publications. 

7.3.1.    Announcements. Except as may be expressly permitted under Section 7.2.3, neither Party will make any
public announcement regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement will prevent (a) either Party from making any public disclosure relating to this Agreement if
the contents of such public disclosure have previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates; (b) Allogene from making any scientific publication or public announcement with
respect to any Allogene Licensed Product Targeting such Allogene Target under this Agreement; provided, however, that, except as permitted under Section 7.2, Allogene will not disclose any of Cellectis’ Confidential Information in any such
publication or announcement without obtaining Cellectis’ prior written consent to do so and (c) Cellectis from making any scientific publication or public announcement with respect to any Cellectis Licensed Product Targeting such Cellectis
Program Target under this Agreement; provided, however, that, except as permitted under Section 7.2, Cellectis will not disclose any of Allogene’s Confidential Information in any such publication or announcement without obtaining
Allogene’s prior written consent to do so. 
 7.3.2.    Publications. During the Term, each Party will submit
to the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information. In addition, each Party will submit to the other Party for its review and approval any proposed publication or public presentation relating to the Research
Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Intellectual Property, Cellectis CAR-T Developed IP and Allogene CAR-T Developed IP and the rights granted to each Party hereunder and determining whether any portion of the proposed publication or presentation containing the Non-Disclosing
Party’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted to the Non-Disclosing Party
no later than thirty (30) days before submission for publication or presentation (the “Review Period”). The Non-Disclosing Party will provide its comments with respect to such
publications and presentations within twenty (20) days after its receipt of such written copy, and the other Party will delete any Confidential Information of the Non-Disclosing Party upon request. The
Review Period may be extended for an additional sixty (60) days in the event the Non-Disclosing Party can, within fifteen (15) days of receipt of the written copy, demonstrate reasonable need for
such extension, including for the preparation and filing of patent applications. Cellectis and Allogene will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties
in any publication governed by this Section 7.3.2. 

  
 39 

 Confidential 
  

 7.4.    Obligations in Connection with Change of Control. If
Cellectis is subject to a Change of Control, Cellectis will, and it will cause its Affiliates and Representatives to, ensure that no Confidential Information of Allogene is released to (a) any Affiliate of Cellectis that becomes an Affiliate as
a result of the Change of Control or (b) any Representatives of Cellectis (or of the relevant surviving entity of such Change of Control) who become Representatives as a result of the Change of Control, unless such Representatives have signed
individual confidentiality agreements which include equivalent obligations to those set out in this Article 7. If any Change of Control of Cellectis occurs, Cellectis will promptly notify Allogene, share with Allogene the policies and
procedures it plans to implement in order to protect the confidentiality of Allogene’s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that are reasonably requested by Allogene.

  

	 	8.	 REPRESENTATIONS AND WARRANTIES. 

8.1.      Mutual Representations and Warranties. Each of Cellectis and Allogene hereby represents and
warrants to the other Party that: 
 8.1.1.    it is duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization; 
 8.1.2.    the execution, delivery and performance of this Agreement by
such Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting
securities or voting interests; 
 8.1.3.    it has the power and authority to execute and deliver this Agreement and to
perform its obligations hereunder; 
 8.1.4.    this Agreement has been duly executed and is a legal, valid and Binding
Obligation on each Party, enforceable against such Party in accordance with its terms; and 
 8.1.5.    the execution,
delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective
Date.  
 8.2.      Representations and
Warranties of Cellectis. Cellectis hereby represents and warrants to Allogene that: 
 8.2.1.    it has and will
have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to Allogene or Allogene’s Affiliates under this Agreement; 

8.3.      Representations and Warranties of Allogene. Allogene hereby represents and warrants to Cellectis
that: 

  
 40 

 Confidential 
  

 8.3.1.    it has and will have the full right, power and authority to
grant all of the right, title and interest in the licenses and other rights granted or to be granted to Cellectis or Cellectis’s Affiliates under this Agreement. 

8.4.    Mutual Covenants. In addition to the covenants made by the Parties elsewhere in this Agreement, each Party
hereby covenants to the other that, from the Effective Date until expiration or termination of this Agreement: 

8.4.1.    it will not (a) take any action that diminishes the rights under the Licensed Cellectis Intellectual
Property or Licensed Allogene Intellectual Property or Developed IP granted or assigned under this Agreement or (b) fail to take any action that is reasonably necessary to avoid diminishing the rights under the Licensed Cellectis Intellectual
Property, Licensed Allogene Intellectual Property or Developed IP granted or assigned to Allogene or Allogene’s Affiliates under this Agreement; 

8.4.2.    it will (a) not enter into any Third Party Agreement that adversely affects (i) the rights granted to
the other Party hereunder or (ii) its ability to fully perform its obligations hereunder; (b) not amend, terminate or otherwise modify any Third Party Agreement (including for Cellectis, the Servier Agreement) or consent or waive rights
with respect thereto in any manner that (i) adversely affects the rights granted to the other Party hereunder or (ii) its ability to fully perform its obligations hereunder; (c) fulfill, and cause its Affiliates to fulfill, all of
their respective obligations under all Third Party Agreements (including for Cellectis Servier Agreements) so as not to be in breach of such agreements; (d) inform Allogene of existence of all notices received by Cellectis or its Affiliates
relating to any alleged breach or default by Cellectis or its Affiliates under any Third Party Agreement (including Servier Agreement), and all other notices received by Cellectis or its Affiliates in connection with any Cellectis Third Party
Agreement that pertain to the rights granted to Allogene or Allogene’s Affiliates hereunder, within [***] after receipt thereof; and (e) in the event that Cellectis does not resolve any such alleged breach or default, notify Allogene
within a sufficient period of time before the expiration of the cure period for such breach of default under such Cellectis Third Party Agreement such that Allogene is able to cure or otherwise resolve such alleged breach or default, and if Allogene
makes any payments to any Third Party in connection with the cure or other resolution of such alleged breach or default, then Allogene may credit the amount of such payments against any royalties or other amounts payable to Cellectis pursuant to
this Agreement. 
 8.4.3.    It will perform and discharge its obligations under this Agreement in conformance with
Applicable Laws. 
 8.4.4.    it will not enter into or otherwise allow itself or its Affiliates to be subject to any
agreement or arrangement which limits the ownership rights of the other Party or its Affiliates with respect to, or limits the ability of the other Party or its Affiliates to grant a license, sublicense or access, or provide or provide access or

  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 41 

 Confidential 
  

 
other rights in, to or under, any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each
case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to the other Party or its Affiliates pursuant to this Agreement; and 

8.4.5.    it shall not, and shall not permit any of its subsidiaries and Affiliates or any of its or their respective
directors, officers, managers, employees, independent contractors, representatives or agents (collectively, “Reps”) to, promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly,
any non-U.S. government official, in each case, in violation of the U.S. Foreign Corrupt Practices Act, as amended (“FCPA”) or any other applicable anti-bribery or anti-corruption law. 

8.4.6.    it shall, and shall cause each of its subsidiaries and Affiliates to, cease all of its or their respective
activities, as well as remediate any actions taken by it, its subsidiaries or Affiliates or any of its or their respective Reps in violation of the FCPA or any other applicable anti-bribery or anti-corruption law. 

8.4.7.    it shall, and shall cause each of its Affiliates and subsidiaries to, maintain systems or internal controls
(including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law. 

8.5.    Representation by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel
in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the
Party which drafted such terms and provisions. 
 8.6.    Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES
OF EACH PARTY ARE IN LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY
EXCLUDED AND DISCLAIMED. 
  

	9.	 GOVERNMENT APPROVALS; TERM AND TERMINATION. 

9.1.    Government Approvals. Each of Cellectis and Allogene will cooperate with the other Party and use
Commercially Reasonable Efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits
and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. 

9.2.    Term. The term of this Agreement (the “Term”) will commence on the Effective Date and will
extend, unless this Agreement is terminated earlier in accordance with this 

  
 42 

 Confidential 
  

 
Article 9, on an Allogene Licensed Product-by-Allogene Licensed Product and country-by-country basis, until such time as the Royalty Term with respect to the sale of such Allogene Licensed Product in such country expires. 

9.3.    Termination by Either Party for Cause. Either Party may terminate this Agreement, in its entirety or, at the
terminating Party’s option, on an Allogene Target-by-Allogene Target basis or Cellectis Program Target-by Cellectis Program
Target basis, as applicable, at any time during the Term of this Agreement by giving written notice to the other Party if the other Party commits a material breach of its obligations under this Agreement and such breach remains uncured for ninety
(90) days, measured from the date written notice of such breach is given to the breaching Party. Notwithstanding the foregoing, a Party will have the right to terminate this Agreement pursuant to this Section 9.3: (a) in part with respect
to an individual Allogene Target or Cellectis Program Target, as applicable, only if the other Party’s material breach giving rise to such termination right relates to such Allogene Target or Cellectis Program Target, as applicable, or
(b) in its entirety only if such material breach fundamentally frustrates the objectives or transactions contemplated by this Agreement taken as a whole. 

9.4.    Termination by Allogene for Convenience. Allogene will have the right to terminate this Agreement for any or
no reason, either in its entirety or on an Allogene Target-by-Allogene Target basis, by providing sixty (60) days advance written notice of such termination to
Cellectis. 
 9.5.    Termination on Insolvency of Cellectis. This Agreement may be terminated upon written notice
by Allogene at any time in the event of a Cellectis Insolvency Event. 
 9.6.    Effects of Termination. 

9.6.1.    Effect of Termination by Allogene for Cause. If Allogene terminates this Agreement with respect to any or
all Allogene Targets pursuant to Section 9.3 (each, a “Terminated Target”): 
 (a)    all licenses
granted to Allogene with respect to such Terminated Target and any Allogene Licensed Product Targeting such Terminated Target (each, a “Terminated Allogene Licensed Product”), including under Section 4.1, will continue and
become irrevocable and perpetual, and Allogene will have no further obligations to Cellectis under this Agreement with respect to any such Terminated Target or Terminated Allogene Licensed Product (including no further obligation to pay Milestone
Payments) other than (i) those obligations that expressly survive termination in accordance with Section 9.8 and (ii) an obligation to pay royalties with respect to Net Sales of Terminated Allogene Licensed Products in accordance with
the terms and conditions of this Agreement, in an amount equal to [***] of the amount that would otherwise have been payable under this Agreement; 

  
 43 

 Confidential 
  

 (b)    If Allogene terminates this Agreement in its entirety pursuant to
Section 9.3, or if Allogene terminates this Agreement in its entirety pursuant to Section 9.4: (i) all licenses granted by Allogene to Cellectis under Sections 4.2.1 and 4.2.2 will terminate, (ii) Allogene will have no further
obligations to Cellectis under this Agreement other than those obligations that expressly survive termination in accordance with Section 9.8, and (iii) any material or Confidential Information provided Allogene to Cellectis in the course
of the performance of this Agreement will be returned or destroyed as directed in writing by Allogene; 

(c)    Allogene will have the right to offset, against any payment owing to Cellectis under subparagraph (b) above,
any damages found or agreed by the Parties to be owed by Cellectis to Allogene; 
 (d)    Cellectis will remain entitled
to receive payments that accrued before the effective date of such termination; 
 (e)    nothing in this
Section 9.6.1 will limit any other remedy Allogene may have for Cellectis’ breach of this Agreement; and 

(f)    the rights and obligations of the Parties with respect to all Allogene Targets other than any such Terminated
Target will remain in full force and effect. 
 9.6.2.    Effect of Termination by Allogene on Insolvency of
Cellectis. If Allogene terminates this Agreement pursuant to Section 9.5: 
 (a)    Cellectis will have no
further obligation to perform any of its obligations under this Agreement other than those obligations that expressly survive termination of this Agreement in accordance with Sections 9.6.2(b) and 9.8; 

(b)    all licenses granted to Allogene, including under Section 4.1, will continue and become, subject only to the
royalty obligation set forth below in this Section 9.6.2(b), irrevocable and perpetual, and Allogene will have no further obligations to Cellectis under this Agreement (including no further obligation to pay Milestone Payments) other than
(i) those obligations that expressly survive termination in accordance with Section 9.8 and (ii) an obligation to pay royalties with respect to Net Sales of Allogene Licensed Products in accordance with the terms and conditions of
this Agreement; 
 (c)    Cellectis will remain entitled to receive payments that accrued before the effective date of
such termination; 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 44 

 Confidential 
  

 (d)    Allogene will have the right to offset, against any payment owing
to Cellectis under subparagraph (b) above, any damages found or agreed by the Parties to be owed by Cellectis to Allogene; and 

(e)    nothing in this Section 9.6.2 will limit any other remedy Allogene may have for Cellectis’ breach of this
Agreement. 
 9.6.3.    Effect of Termination by Cellectis for Cause or by Allogene for Convenience. 

(a)    If Cellectis terminates this Agreement with respect to any Allogene Target pursuant to Section 9.3, or if
Allogene terminates this Agreement with respect to any Allogene Target pursuant to Section 9.4, then (i) all licenses granted by Cellectis to Allogene under Sections 4.1.1, 4.1.2 and 4.1.3 with respect to any such Allogene Target will
terminate, (ii) any Allogene Licensed Product Targeting such Allogene Target will terminate, and (iii) any material or Confidential Information provided by Cellectis to Allogene in the course of the performance of this Agreement will be
returned or destroyed as directed in writing by Cellectis. 
 (b)    If Cellectis terminates this Agreement in its
entirety pursuant to Section 9.3, or if Allogene terminates this Agreement in its entirety pursuant to Section 9.4: (i) all licenses granted by Cellectis to Allogene under Sections 4.1.1, 4.1.2 and 4.1.3 will terminate, (ii) all
rights and licenses granted by Cellectis to Allogene pursuant to Section 4.1.2(b) and 4.1.2(d), and all obligations to which the parties are bound hereunder with relation thereto, will continue in full force and effect, to the extent such
rights and licenses were not previously or concurrently terminated (including as set forth in Section 9.6.3(a) herein) and will subsequently terminate in accordance with the terms of the Servier Agreement, wherein such rights and licenses were
initially granted to Servier, (iii) Cellectis will have no further obligations to Allogene under this Agreement other than those obligations that expressly survive termination in accordance with Section 9.8, (iv) all rights and
licenses granted by Allogene to Cellectis pursuant to Section 4.2 will continue, (v) Allogene’s right of first refusal set forth in Section 3.6 will continue to the extent that such Cellectis Product is Covered by Licensed
Allogene Intellectual Property and (vi) any material or Confidential Information provided by Cellectis to Allogene in the course of the performance of this Agreement will be returned or destroyed as directed in writing by Cellectis. For the
avoidance of doubt, all rights and licenses granted by Cellectis to Allogene pursuant to Section 4.1.2(b) and 4.1.2(d), and all obligations to which the parties are bound hereunder with relation thereto, will terminate immediately upon the
earlier to occur of (i) termination or expiration of the license granted by Cellectis to Servier in respect of the [***] Patent Rights for the Other Products pursuant to the Servier Agreement, or (ii) on an Other Product-by-Other Product basis, termination or expiration of the license 

  
 45 

 Confidential 
  

 
granted by Servier to Allogene in respect of an Other Product pursuant to the Exclusive License and Collaboration Agreement dated as of October 30, 2015 by and between Allogene and Servier
(as amended from time to time). 
 (c)    In the event that Cellectis terminates this Agreement for cause pursuant to
Section 9.3 or Allogene terminates this Agreement without cause pursuant to Section 9.4 with respect to an Allogene Licensed Product Targeting an Allogene Target, on Cellectis’ written notice to Allogene, which notice may only be
delivered within [***] following the effective date of such termination, unless such termination is related to material concerns regarding the safety of the Compound(s) or Product(s), the Parties will negotiate in good faith for a period not to
exceed [***] following the effective date of termination regarding: 
 (i)    the grant by Allogene to Cellectis of a
royalty-bearing, non-exclusive license under the Applicable Allogene Technology permitting Cellectis to continue to Develop, Commercialize and Manufacture any Product under Development or Commercialization by
Allogene under this Agreement at the time of termination, in the form in which such Product then exists (a “Continuation Product”); and 

(ii)    the related transfer to Cellectis of development data and regulatory filings specifically relating to such
Continuation Product or the granting to Cellectis of rights of reference with respect to such data and filings. 

(d)    Neither Party will be obligated to enter into any transaction described in Section 9.6.3(c) and neither Party
will have any liability to the other for failure to do so. 
 (e)    For the avoidance of doubt, if Cellectis terminates
this Agreement with respect to any Allogene Target pursuant to Section 9.3, or if Allogene terminates this Agreement with respect to any Allogene Target pursuant to Section 9.4, in each case including all Allogene Targets in the event that
this Agreement is terminated in its entirety, any such Allogene Target will no longer be considered to be an Allogene Target for the purpose of this Agreement. 

9.6.4.    Satisfaction of Obligations During Notice Period. During the period from providing a notice of
termination through the termination of the Agreement, the Parties will continue to perform their obligations under this Agreement. 

9.6.5.    Pending Dispute Resolution. If a Party gives notice of termination under Section 9.3 and the other
Party disputes whether such notice was proper, then the 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 

  
 46 

 Confidential 
  

 
issue of whether this Agreement has been terminated will be resolved in accordance with Section 11.10 and this Agreement will remain in effect pending the resolution of such dispute. If as a
result of such dispute resolution process it is determined that the notice of termination was proper, then such termination will be effective immediately. If as a result of such dispute resolution process it is determined that the notice of
termination was improper, then no termination will have occurred and this Agreement will remain in effect. 

9.7.    Disposition of Inventories of Products. Following termination of this Agreement with respect to one or more
Allogene Targets, Allogene, its Affiliates and its Sublicensees will have the right to continue to sell their existing inventories of Allogene Licensed Product(s) Targeting such Allogene Targets that have received Regulatory Approval prior to such
termination for a period not to exceed [***] after the effective date of such termination or expiration and Allogene will pay any royalties payable in connection with such sales in accordance with Section 5.2. 

9.8.    Survival of Certain Obligations. Expiration or termination of this Agreement will not relieve the
Parties of any obligation that accrued before such expiration or termination. The following provisions will survive expiration or termination of this Agreement: Sections 1(Definitions); 5.4.2 to 5.4.6 (Reports and Payments); 5.5 (Maintenance
and Audit Rights); 7 (Confidentiality); 8 (Representations and Warranties); 9.3 to 9.8 (Effect of Termination); 10 (Limitation on liabilities) and 11 (Miscellaneous). In addition, any Section that is referred to in the above listed Sections shall
survive solely for the interpretation or enforcement of the listed Sections. 
 9.9.    Right to Terminate this
Agreement by Allogene upon Change of Control of Cellectis. If a Change of Control of Cellectis is consummated during the Term of this Agreement, Allogene will have the right to terminate this Agreement in its entirety, upon written notice
to Cellectis within sixty (60) days after consummation of such Change of Control of Cellectis. 

9.10.    Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Cellectis are, and will
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that Allogene, as
licensee of intellectual property under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that in the event of a rejection of this Agreement by Cellectis in
any bankruptcy proceeding by or against Cellectis under the U.S. Bankruptcy Code, (i) Allogene will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such
intellectual property, which, if not already in Allogene’s possession, will be promptly delivered to it upon Allogene’s written request therefor, and (ii) Cellectis will not interfere with Allogene’s rights to intellectual
property and all embodiments of intellectual property, and will assist and not interfere with Allogene in obtaining intellectual property and all embodiments of intellectual property from another 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 47 

 Confidential 
  

 
entity. The term “embodiments” of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and
products embodying intellectual property, Allogene Licensed Products, filings with Regulatory Authorities and related rights, and Cellectis Technology. 
  

	10.	 LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE. 

10.1.    No Consequential Damages. Except with respect to liability arising from a breach of Article 7, from
any willful misconduct or intentionally wrongful act, or to the extent such Party may be required to provide indemnification under this Article 10, in no event will either Party, its Affiliates, its Sublicensees or any of its, its
Affiliates’ or its Sublicensees’ respective Representatives be liable under this Agreement for any special, indirect, incidental, consequential or punitive damages, whether in contract, warranty, tort, negligence, strict liability or
otherwise, including loss of profits or revenue suffered by either Party or any of its respective Affiliates or Representatives. Without limiting the generality of the foregoing, “consequential damages” will be deemed to include, and
neither Party will be liable to the other Party or any of such other Party’s Affiliates, Representatives or stockholders for, any damages based on or measured by loss of projected or speculative future sales of the Allogene Licensed Products,
any Milestone Payment due upon any unachieved event under Section 5.1, any unearned royalties under Section 5.2 or any other unearned, speculative or otherwise contingent payments provided for in this Agreement. 

10.2.    Indemnification by Allogene. Allogene will indemnify, defend and hold harmless Cellectis, its Affiliates,
their sublicensees, contractors, subcontractors and distributors and each of its and their respective employees, officers, directors and agents (each, a “Cellectis Indemnified Party”) from and against any and all liability, loss,
damage, expense (including reasonable attorneys’ fees and expenses) and cost (collectively, a “Liability”) that the Cellectis Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out
of: 
 10.2.1.    [***] 

10.2.2.    [***] 

[***] 

10.3.    Indemnification by Cellectis. Cellectis will indemnify, defend and hold harmless Allogene, its
Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a “Allogene Indemnified Party”) from and against any and all Liabilities that the Allogene
Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 

10.3.1.    [***] 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 48 

 Confidential 
  

 10.3.2.    [***] 

[***] 

10.4.    Procedure. 

10.4.1.    Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for
which indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the “Indemnified Party”)
is entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnified Party will promptly notify the Party obligated to indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided,
however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby.

 10.4.2.    Control. Subject to Allogene’s right to control any actions described in Section 6.2 (even
where Cellectis is the Indemnifying Party), the Indemnifying Party will have the right, exercisable by notice to the Indemnified Party within ten (10) Business Days after receipt of notice from the Indemnified Party of the commencement of or
assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel
selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of
any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the
Indemnifying Party will be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the “Litigation Conditions”). Within
ten (10) Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party will give notice to the Indemnifying Party of any objection thereto
based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party will continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If
no such notice is given, or if any such objection is withdrawn, the Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably
acceptable to the Indemnified Party. During such time as the 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 49 

 Confidential 
  

 
Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party will cooperate, and will cause its Affiliates and agents to cooperate upon request of the
Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be
requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party’s intent to defend any Third Party Claim within ten
(10) Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified Party, as the case may be, will have the right
to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim that the other Party is defending as
provided in this Agreement. 
 10.4.3. Settlement. The Indemnifying Party will not, without the prior written consent of the
Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party will have the sole and exclusive right to settle any Third Party Claim, on such terms and
conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but will not have the right to settle such Third Party Claim to the extent
such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party will not make any admission of liability in respect of any Third Party Claim
without the prior written consent of the other Party, and the Indemnified Party will use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

10.5.    Insurance. Each Party will obtain and maintain, during the Term, commercial general liability insurance,
including products liability insurance, with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification obligations under Section 10.2
or Section 10.3, as applicable, in each case with limits of not less than [***] per occurrence and in the aggregate. 
  

	11.	 MISCELLANEOUS. 

11.1.    Other Cellectis Targets. For sake of clarity, except as set forth in Schedule 1.86 and
Section 3.7 (Right of Negotiation), Other Cellectis Targets are outside the scope of this Agreement. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 50 

 Confidential 
  

 11.2.    Assignment. Either Party may not assign this Agreement or
any interest hereunder without the prior written consent of the other, which consent will not be unreasonably withheld or delayed., except that this Agreement may be assigned as follows: (a) a Party may assign its rights and obligations under
this Agreement by way of sale of itself or the sale of the portion of its business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest and (b) a Party may assign its rights and obligations
under this Agreement to any of its Affiliates. This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and
permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 11.2 will be void. 

11.3.    Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do
all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

11.4.    Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement to
the extent that such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force
majeure continues and the nonperforming Party takes Commercially Reasonable Efforts to resume performance. For purposes of this Agreement, “force majeure” will include conditions beyond the control of the Parties, including an act of God,
voluntary or involuntary compliance with any Applicable Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common
carriers, or destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 

11.5.    Notices. Any notice or notification required or permitted to be provided pursuant to the terms and
conditions of this Agreement (including any notice of force majeure, breach, termination, change of address, etc.) will be in writing and will be deemed given upon receipt if delivered personally or by facsimile or email transmission (receipt
verified), five days after deposited in the mail if mailed by registered or certified mail (return receipt requested) postage prepaid, or on the next Business Day if sent by overnight delivery using a nationally recognized express courier
service and specifying next Business Day delivery (receipt verified), to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a Party as will be specified by like notice, provided, however,
that notices of a change of address will be effective only upon receipt thereof): 
 All correspondence to Allogene will be addressed as
follows: 
 Allogene Therapeutics, Inc. 

210 East Grand Avenue 
 South San
Francisco, CA 94080 
 USA 

Attention: General Counsel 

Email: [***] 

  
 51 

 Confidential 
  

 All correspondence to Cellectis will be addressed as follows:     

Cellectis 
 8, rue de la Croix
Jarry 
 75013 Paris 
 Attn.:
Chief Executive Officer 
 Fax.: +33 1 81 69 16 03 

Email: [***] 
 with a copy to:

 Cellectis 
 8, rue de la
Croix Jarry 
 75013 Paris 

Attn.: General Counsel 
 Fax.: +33
1 81 69 16 03 
 Email: [***] 

11.6.    Amendment. No amendment, modification or supplement of any provision of this Agreement will be valid or
effective unless made in writing and signed by a duly authorized officer of each Party. 
 11.7.    Waiver. No
provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The
waiver by either of the Parties of any breach of any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

11.8.    Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid,
illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the
greatest extent possible. In any such event, this Agreement will be construed as if such clause or portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out
the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 

11.9.    Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will
be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
 11.10.    Dispute
Resolution. If any dispute or disagreement arises between Allogene and Cellectis in respect of this Agreement, they will follow the following procedures in an attempt to resolve the dispute or disagreement: 

11.10.1.    The Party claiming that such a dispute exists will give notice in writing (a “Notice of
Dispute”) to the other Party of the nature of the dispute. 
  

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 

  
 52 

 Confidential 
  

 11.10.2.    Within [***] of receipt of a Notice of Dispute, the Allogene
Alliance Manager and the Cellectis Alliance Manager will meet in person or by teleconference and exchange written summaries reflecting, in reasonable detail, the nature and extent of the dispute, and at this meeting they will use their reasonable
endeavors to resolve the dispute. 
 11.10.3.    If the Alliance Managers are unable to resolve the dispute during the
meeting described in Section 11.10.2 or if for any reason such meeting does not take place within the period specified in Section 11.10.2, then the Chief Executive Officer of Allogene and the Chief Executive Officer of Cellectis will meet
at a mutually agreed-upon time and location for the purpose of resolving such dispute. 
 11.10.4.    If, within a
further period of [***], or if in any event within [***] of initial receipt of the Notice of Dispute, the dispute has not been resolved, or if, for any reason, the meeting described in Section 11.10.3 has not been held within [***] of initial
receipt of the Notice of Dispute, then the Parties agree that, subject to Section 11.11 below, either Party may initiate litigation to resolve the dispute. 

11.11.    Election of Resolution Process. Notwithstanding any provision of Section 11.10 to the contrary, if
(i) either Party raises any allegation or claim of Misuse (each, a “Misuse Allegation”) and (ii) the Parties are unable to resolve such Misuse Allegation pursuant to the dispute escalation process described in
Sections 11.10.1 through 11.10.4 (the “Escalation Process”), then, following completion of the Escalation Process, the Parties may mutually agree to have such Misuse Allegation resolved pursuant to the terms of
Section 11.12 (Arbitration Process). If the Parties fail to agree on use of arbitration pursuant to Section 11.12 in a timely manner (not to exceed [***]), then the Parties will be deemed to have elected to have such Misuse Allegation
resolved through litigation. 
 11.12.    Arbitration Process. If the Parties mutually elect to resolve any Misuse
Allegation pursuant to this Section 11.12, then such Misuse Allegation will be referred to and finally resolved by binding arbitration in accordance with the Commercial Rules and Procedures (the “Rules”) of the International
Chamber of Commerce (the “ICC”), by an arbitral tribunal composed of three arbitrators, all of whom will have relevant experience in pharmaceutical industry, appointed by agreement of the Parties in accordance with the Rules. If, at
the time of the arbitration, the Parties agree in writing to submit the dispute to a single arbitrator, said single arbitrator will (1) have relevant experience in pharmaceutical industry and (2) be appointed by agreement of the Parties,
or, failing such agreement, by ICC in accordance with the Rules. The foregoing arbitration proceedings may be commenced by either Party by written notice to the other Party. Unless otherwise agreed by the Parties hereto, all such arbitration
proceedings will be held in London, England, provided that proceedings may be conducted by telephone conference call with the consent of both Parties and the arbitrator(s). All arbitration proceedings will be conducted in the English language. 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 53 

 Confidential 
  

 11.12.1.     Limited Discovery. Documentary discovery may be
conducted at the discretion of the arbitrator(s), provided that any such discovery will (a) be limited to documents directly relating to the Misuse Allegation, (b) be conducted pursuant to document discovery procedures as set forth under
the laws of the State of New York, U.S.A., (c) be conducted subject to the schedule stipulated by the Parties, or in the absence of stipulation, the schedule ordered by the arbitrator(s), and (d) not require either Party, its Affiliates or
their respective employees, officers, directors or agents to be subject to deposition. Notwithstanding any provision of this Section 11.12.1 to the contrary, all discovery must be completed within sixty (60) days of the notice of
commencement of arbitration proceedings. 
 11.12.2.    Awards and Fees. The arbitrator(s) may only consider
awards of direct monetary damages and will not under any circumstances have the authority to grant (a) injunctive relief, (b) equitable relief, (c) orders for specific performance, (d) punitive damages or (e) consequential
damages as described in Section 10.1. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrator(s), or, in the absence of such determination, each Party will pay its own
expenses. 
 11.12.3.    Rulings. All arbitration proceedings must be completed within 180 days of the notice of
commencement of arbitration proceedings. The Parties hereby agree that, subject to the provisions of this Section 11.12.3, the arbitrator(s) has authority to issue rulings and orders regarding all procedural and evidentiary matters that the
arbitrator(s) deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and judgment. Rulings will be issued by written order summarizing the arbitration proceedings no more than 30 days after the
final submissions of the Parties. All rulings by the arbitrator(s) will be final and non-appealable to any court except in circumstances where such rulings do not comply with the terms of Section 11.12.

 11.12.4.    Enforcement of Rulings by Courts of Competent Jurisdiction. Any ruling issued by the arbitrator(s)
pursuant to Section 11.12 may be enforced, to the extent that such ruling complies with the provisions of Section 11.12, in any court having jurisdiction over any of the Parties or any of their respective assets. 

11.12.5.    Confidentiality. All activities undertaken by the arbitrator(s) or the Parties pursuant to this
Section 11.12 will be conducted subject to obligations of confidentiality no less restrictive than those set forth in Article 7. Further, the Parties acknowledge and agree that their respective conduct during the course of the arbitration
and their respective statements and all information exchanged in connection with the arbitration is Confidential Information under this Agreement and subject to the provisions of Article 7. 

  
 54 

 Confidential 
  

 11.12.6.    Unauthorized Disclosure of Confidential Information to
Third Parties. Notwithstanding any provision of this Agreement to the contrary (i) the provisions of this Section 11.12 will not apply to Allogene’s disclosure of Cellectis Confidential Information to any Third Party in violation
of Article 7 and (ii) Cellectis reserves its rights under Section 11.10 to immediately initiate litigation seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve
or enforce its rights under Article 7 with respect to any such unauthorized disclosure. 

11.13.    Governing Law. This Agreement, and all claims arising under or in connection therewith, will be
governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof. 

11.14.    Consent to Jurisdiction. Each Party to this Agreement, by its execution hereof, (a) hereby
irrevocably submits to the exclusive jurisdiction of the courts of England and Wales for the purpose of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the
subject matter hereof, (b) hereby waives to the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction
of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred to any court
other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in
or by such court, and (c) hereby agrees not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to
any court other than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. 

11.15.    Entire Agreement. This Agreement, including its Exhibits and Schedules, and the letter regarding
termination of the Research Collaboration and License Agreement, dated 7, 2019, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations,
correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof. 

11.16.    Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing
herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for
the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in
any respect whatsoever. 

  
 55 

 Confidential 
  

 11.17.    Counterparts. This Agreement may be executed in two
counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which will be binding when received by the applicable Party.

 11.18.    No Third Party Rights or Obligations. No provision of this Agreement will be deemed or construed in
any way to result in the creation of any rights or obligation in any Person not a Party to this Agreement. However, Allogene may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder,
provided that Allogene will remain liable hereunder for the performance by any such Affiliates of any such obligations. 
 [The remainder
of this page has been intentionally left blank. The signature page follows.] 

  
 56 

 Confidential 
  

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date. 
  

							
	ALLOGENE THERAPEUTICS, INC.	  	CELLECTIS SA
				
	By:	 	/s/ David Chang, M.D., Ph.D.	  	By:	 	/s/ André Choulika
	Name: 	 	David Chang, M.D., Ph.D.	  	Name: 	 	André Choulika
	Title:	 	Chief Executive Officer	  	Title:	 	Chief Executive Officer

  

 Confidential 
  

 Schedule 1.13 

Allogene Targets 
 [***] 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 Confidential 
  

 Schedule 1.32 

Cellectis Patent Rights 
 [***] 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 Confidential 
  

 Schedule 1.34 

Cellectis Performance Targets 
 [***] 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 Confidential 
  

 Schedule 1.86 

Other Cellectis Targets 
 [***] 

 

	[***]	 CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 Confidential 
  

 Schedule 9.23 

[***] Patent Rights 
 [***] 

[***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]